ATG7 drives cell fate decisions in kidney tubule homeostasis and disease

Daniela Nieri[1,19], Svenja Aline Keller[1,19], Louise Pierre[1], Federica Carloni[1], Roberto Pili[2], Zhiyong Chen[1], Adia M. Ouellette[3,4], Marine Berquez[1], Patrick Krohn[1], Andrea Raimondi[5,6], Valeria Berno[6], Martina Zanella[7], Michelle Elisabeth Reid[7], Alaa Othman[7], Andrew M. Schaefer[8,9], Eric Gregory Olinger[10,11], John A. Sayer[11,12,13], Alina Ustiugova[14], Mikhail Korzinkin[14], Stephan C.F. Neuhauss[15], Christian Münz[16], Robert McFarland[8,9], Robert W. Taylor[8,9], Louis R. Lapierre[3,4], Elisa Araldi[2,17], Olivier Devuyst[1,18,20], and Alessandro Luciani[1,20]

[1] Institute of Physiology, University of Zurich, 8057 Zurich, Switzerland

[2] Systems Medicine Laboratory, Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy

[3] Department of Chemistry and Biochemistry, University of Moncton, NB E1A 3E9 Moncton, Canada

[4] New Brunswick Center for Precision Medicine, 27 rue Providence, Moncton, NB E1C 8X3, Canada

[5] Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), CH-6500 Bellinzona, Switzerland

[6] San Raffaele Scientific Institute, Experimental Imaging Center, 20132 Milan, Italy

[7] Functional Genomics Center Zurich, University of Zurich, 8057, Zurich, Switzerland

[8] Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

[9] NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK

[10] Center for Human Genetics Cliniques Universitaires Saint-Luc, UCLouvain, 1200 Brussels Belgium

[11] Biosciences Institute, Faculty of Medical Sciences, Newcastle University, NE Newcastle upon Tyne, NE1 3BZ, UK

[12] Renal Services, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK

[13] NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, NE4 5PL, United Kingdom

[14] Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, Hong Kong SAR, China

[15] Department of Molecular Life Sciences, and [16] Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland

[17] Computational Biomedicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany

[18] Institute for Rare Diseases, Cliniques Universitaires Saint-Luc, UCLouvain Medical School, B1200 Brussels, Belgium

[19] These authors contributed equally

[20] Co-directed the study and co-last authors

Correspondence: alessandro.luciani@uzh.ch

Summary

Metabolism and differentiation in the kidney proximal tubule (PT) must be tightly coordinated to maintain homeostasis, yet determinants of metabolic cell-fate decisions remain undefined. Here, we combine model organisms with multi-omics landscapes and human genetics to identify the autophagy enzyme ATG7 as a key metabolic driver of PT-cell fate specialization. In mice, PT-specific deletion of ATG7 forces differentiated cells into anabolic, proliferative states, compromising nutrient reabsorption. Mechanistically, loss of ATG7 impairs clearance of lipid droplets, restricts fatty-acid (FA) metabolism, and depletes energy required for normal PT physiology. In zebrafish pronephros, re-expression of wild-type ATG7 rescues reabsorption in *atg7* mutants, whereas inhibiting FA oxidation triggers dysfunction. In humans, *ATG7* variants associate with cardio-kidney-metabolic health and increased disease risk, whereas low *ATG7* levels predict poor survival in clear cell renal carcinoma. These findings establish a conserved paradigm coupling ATG7/autophagy and metabolism to epithelial cell-fate decisions, thus carrying implications for health and disease.

Introduction

Specialized epithelial cells must integrate metabolic programs with differentiation cues to execute their unique functions and preserve homeostasis.[1] A paradigm for this concept is provided by the cells lining the kidney's proximal tubule (PT). These cells recover ultrafiltered plasma proteins and solutes via receptor-mediated endocytosis — capturing low-molecular-weight ligands through LRP2/megalin and CUBN/cubilin — and deliver them to lysosomes for degradation, while recycled receptors return to the membrane.[2-4]

This constant cycle of uptake, endomembrane trafficking, and nutrient processing imposes a tremendous amount of energy and ATP expenditure, and their dysregulation — whether congenital or acquired — impairs PT function, leading to the appearance in the urine of essential nutrients and causing potentially life-threatening metabolic complications.[2,3]

Simultaneously, macroautophagy/autophagy sequesters intracellular macromolecules and organelles into autophagosomes for lysosomal turnover, sustaining cellular metabolism and tissue homeostasis.[5] Although both lysosomal failure and autophagy defects undermine PT cell differentiation and their reabsorptive activities,[6-7] they act at distinct steps: lysosomal dysfunction stalls cargo degradation, whereas loss of core autophagy regulators blocks autophagosome biogenesis or maturation.

Central to autophagosome formation is ATG7 — a conserved E1-like enzyme that conjugates ATG12 to ATG5 and lipidates MAP1LC3-I into MAP1LC3-II, a bona fide biosensor for monitoring autophagy levels in cells and tissues.[8-11] Global ATG7 knockout in mice can cause neonatal lethality and metabolic collapse,[12-13] while PT-specific deletion overwhelms adaptive repair pathways in response to cellular stressors, promoting macromolecular damage and dysfunction.[14,15] While ATG7-mediated autophagy is well known for its role in clearing cellular stress and promoting resilience, its basal function in guiding PT-cell differentiation and specialization remains poorly understood.

The kidney is one of the most metabolically active organs, requiring continuous ATP production and consumption to support energy-intensive processes, including reabsorption

and transport of nutrients and multiple solutes.[16] Tubular epithelial cells are densely packed with mitochondria, reflecting their reliance on fatty-acid β-oxidation (FAO) and oxidative phosphorylation to meet energetic demands.[17,18]

Impairment of mitochondrial function — characterized by reduced electron-transport chain activity, diminished oxidative metabolism and ATP production, and increased reactive oxygen species (ROS) — disrupts PT bioenergetics and alters epithelial differentiation, contributing to the onset and progression of kidney diseases.[6,7,19]

In preclinical models, both genetic and pharmacological enhancement of autophagy improves mitochondrial quality control, restores FA metabolism and energy production, and alleviates metabolic dysfunction and the progression of kidney disease.[18,20] Furthermore, individuals harbouring biallelic pathogenic variants in *ATG7* exhibit profound autophagy impairment, neurodevelopmental defects, and metabolic derangements.[21] Together, these findings highlight a critical intersection between autophagy and metabolic regulation of differentiation programs and homeostasis in health and disease. However, a mechanism that connects ATG7-mediated autophagy to metabolic cell-fate decisions remains undefined.

Here, we use genetically engineered model organisms and physiologically relevant cell culture systems and integrate them with multi-omics landscapes and population-scale genomics to define how ATG7 integrates autophagy with mitochondrial lipid metabolism and energetic balance to govern epithelial cell-fate specialization in the kidney tubule. We demonstrate that dysregulation of the ATG7-driven autophagy–metabolism axis underlies a spectrum of kidney diseases and influences the progression of renal cell carcinoma, thus offering insight into therapeutic discovery and development.

Results

ATG7 deficiency impairs autophagy in kidney proximal tubule epithelial cells

To define the role of ATG7 deficiency in PT autophagy (**Figure S1A**), we crossed a previously generated *Atg7*$^{fl/fl}$ mouse line[13] with mice expressing Cre recombinase under a PT-specific promoter (γ*Gt1*-Cre; **Figures S1B-1E**).[22] This generated *Atg7*$^{fl/fl}$; γ*Gt1*$^{cre/cre}$ mice (hereafter referred to as *Atg7*$^{PT\text{-}KO}$), in which exon 14 of *Atg7* was efficiently excised (**Figures S1F-S1G**), and corresponding control littermates (*Atg7*$^{fl/fl}$; γ*Gt1*$^{wt/wt}$, hereafter CTR). Conditional *Atg7*$^{PT\text{-}KO}$ mice were viable with expected Mendelian frequencies and gender ratios. The deletion of *Atg7* was validated in the kidney cortex at the mRNA and protein levels (**Figures S2A-S2B**). In line with impaired autophagy, *Atg7*$^{PT\text{-}KO}$ kidneys exhibited markedly reduced levels of the lipidated, autophagosome-associated form of Map1lc3b (Map1lc3b-II; **Figure S2C**) and accumulation of Sequestosome 1 (Sqstm1; ref.11; **Figures S2C-S2D**), indicating autophagy impairment in PT epithelial cells.

Defective ATG7-driven autophagy triggers dyshomeostasis and PT dysfunction

To examine how loss of ATG7-driven autophagy deficiency affects PT homeostasis and normal physiology, we longitudinally tracked a cohort of *Atg7*$^{PT\text{-}KO}$ mice and CTR littermates up to 24 weeks of age (**Figure 1A; Table S1**). Beginning at 12 weeks of age, *Atg7*$^{PT\text{-}KO}$ mice displayed reduced body weight and impaired growth compared to CTR littermates (**Figures 1B-1C**). PT dysfunction was evident as early as 4 weeks, with significantly elevated urinary levels of the low-molecular-weight protein CC16 — an established PT dysfunction marker — in *Atg7*$^{PT\text{-}KO}$ compared to CTR mice, irrespective of gender (**Figures 1D and S3A**). Additional markers of PT impairment, including increased urinary albumin, transferrin (TF), and vitamin D binding protein (VDBP), were also detected (**Figures 1E-1F**), along with abnormal urinary losses of glucose, phosphate, calcium, and amino acids in mutant mice (**Figures 1G-1I and S3B-S3C; Table S1**). Remarkably, despite clear PT functional deficits, *Atg7*$^{PT\text{-}KO}$ kidneys exhibited no evidence of fibrosis, apoptosis, or overt structural abnormalities (**Figures S3E-S3H**), and blood urea nitrogen (BUN), plasma creatinine, and

survival rates remained comparable to controls (**Figures S3I-S3K; Table S2**). Together, these findings establish that ATG7-dependent autophagy is critical for maintaining PT function and homeostasis, and that its disruption leads to a global proximal tubulopathy in the absence of structural kidney damage.

ATG7 deficiency diverts PT towards abnormal growth and proliferation

To assess how ATG7 deficiency alters PT cell identity and phenotype, we examined endocytic capacity, differentiation, and proliferation markers in *Atg7*$^{PT\text{-}KO}$ versus control mice (**Figure 2A**). Fluorescent tracer studies showed a marked impairment in both receptor-mediated (Cy5-lactoglobulin) and fluid-phase (Alexa647-dextran) endocytosis in *Atg7*$^{PT\text{-}KO}$ PTs (**Figure 2B**). Consistently, mRNA levels of key solute transporters (*Slc34a2*, *Slc5a2*) and endocytic receptors (*Lrp2*, *Cubn*) were significantly reduced (**Figure 2C**), and apical localization of LRP2/megalin and transferrin receptor was diminished (**Figures 2D and S4A**), despite preserved expression of core endosomal–lysosomal components (**Figure S4B**). In parallel, *Atg7*$^{PT\text{-}KO}$ PTs upregulated genes associated with cell cycle and proliferation (*Ccna2*, *Ccnb2*, *Cdc20*, *Pcna*, *Ki67*; **Figures 2E-2F**), accompanied by an increased kidney-to-body-weight ratio (**Figure S4C**). Morphologically, PT epithelial cells transitioned from a cuboidal to a columnar phenotype (**Figure S4D**), even though transcription factors that normally couple metabolism to differentiation (*Esrra*, *Hnf1a*, *Hnf4a*, *Ppara*; ref.19,24) remained unchanged (**Figures S4E-S4F**). Together, these findings reveal that ATG7-dependent autophagy is essential for maintaining the specialized, endocytic phenotype of PT cells; its loss triggers a shift toward a proliferative, anabolic state, disrupting epithelial identity and their homeostatic functions, including receptor-mediated endocytosis.

ATG7 deficiency alters autophagy, metabolism, and function in cultured PT cells

To delineate how ATG7 loss disrupts PT-cell phenotype and homeostasis, we analyzed primary mouse proximal tubule cells (mPTCs[6,7]) isolated from *Atg7*$^{PT\text{-}KO}$ and control mice (**Figures 3A, 3B, and 3D**). Compared to control cells, *Atg7*$^{PT\text{-}KO}$ mPTCs exhibited impaired

conversion of Map1lc3b-I to its lipidated form, Map1lc3b-II, and reduced formation of Map1lc3b-positive autophagosomes under both fed and starved conditions (**Figures 3C, 3E, and 3F**). Notably, treatment with the lysosomal inhibitor Bafilomycin A1 (BafA1) increased Map1lc3b-II levels in both starved control and ATG7-deficient cells (**Figures 3C-3E**), suggesting activation of alternative autophagy pathways in response to nutrient/lysosomal stress.[12] Consistent with this, transmission electron microscopy revealed a lower abundance of autophagic vacuoles in BafA1-treated, starved *Atg7*$^{PT\text{-}KO}$ mPTCs (**Figure 3G**). These autophagy defects were accompanied by altered lysosomal dynamics and catabolic function, dysregulated anabolic programs for cell growth and proliferation, and impaired receptor-mediated uptake of fluorescent ligands — phenotypes that mirror the in vivo observations (**Figures 3H-3J and S5A-S5B**). These cellular abnormalities occurred independently of changes in the expression of other core autophagy genes (**Figure S5C**) or major nutrient-sensing pathways, including mTORC1 and AMPK (**Figures S5D-S5E**).[25] Together, these data establish that ATG7-driven autophagy is indispensable for preserving the metabolic trajectories of PT cells and their specialized function, acting through mechanisms that are at least partially independent of canonical nutrient-sensing and signalling pathways.

Loss of ATG7-driven autophagy impairs lipid droplet turnover, triggering lipid storage

To uncover factors driving loss of epithelial cell identity and dysregulated homeostasis downstream of ATG7/autophagy deficiency, we performed proteomic and metabolomic profiling of control and *Atg7*-deficient mPTCs (**Figures S6A-S6D**). Protein-protein interaction (PPI) network analysis of differentially expressed proteins revealed significant enrichment in mitochondria and metabolic pathways, including amino acid and fatty acid (FA) metabolism, the TCA cycle, electron transport, FA oxidation, and energy generation in *Atg7*$^{PT\text{-}KO}$ mPTCs (**Figure S6E**) compared to CTR cells. Combined clustering of metabolites and proteins further highlighted enrichment in FA elongation/degradation, amino acid metabolism, autophagy–lysosome degradation systems, and signatures associated with senescence and cancer metabolism in *Atg7*-deficient mPTCs (**Figure 4A**). Based on these findings, we

hypothesized that ATG7 loss disrupts PT-cell phenotype and homeostasis by impairing the autophagic degradation of lipid droplets (LDs) — a conserved process known as lipophagy.[26] In control mPTCs, fasting triggered a transient increase in LDs at 4–8 hours that normalized by 16 hours, consistent with LD turnover via autophagy, as shown by BODIPY$^{493/503}$ staining (**Figure S7A**). A similar LD clearance pattern was observed following oleic acid (OA) treatment, which promotes triacylglycerol (TAG) accumulation within LDs[27] (**Figure S7B**). Blocking catabolic autophagy with BafA1 or the VPS34 inhibitor SAR405 impaired LD clearance and increased LD size (**Figures S7C–S7E**); BafA1 increased colocalization of LD markers (Plin2, LipidTOX) with the lysosomal marker LAMP1, while SAR405 reduced it (**Figures S7C, S7F, and S7G**), underscoring the reliance of LD turnover and homeostasis on autophagy and lysosome-related pathways.[26] In contrast, *Atg7*-deficient mPTCs exhibited elevated baseline LD levels that failed to decrease during starvation, even in the presence of BafA1 (**Figure 4B**). These cells also accumulated Sqstm1^{+} LDs and showed reduced colocalization between LipidTOX and LAMP1 (**Figures 4B and S8A-S8B**), indicating defective lipophagy. Lipidomic profiling confirmed the accumulation of TAGs and phosphatidylcholines (PCs), as well as altered levels of lysophosphatidylethanolamines (LPEs) and sphingomyelins (SMs) in *Atg7*$^{PT\text{-}KO}$ cells (**Figures 4C and S9A-S9D**). Notably, expression of FA transporters, lipolytic enzymes, mitochondrial/peroxisomal FAO genes, and mitochondrial biogenesis markers remained unchanged (**Figures S10A-S10C**), suggesting that lipid clearance defects stem specifically from impaired lipophagy. Together, these findings demonstrate that ATG7 is required for lipid droplet turnover and metabolic homeostasis in PT cells through a lipophagy-dependent mechanism.

ATG7-driven autophagy couples lipid metabolism to mitochondrial energy production

Lipid catabolism releases fatty acids (FAs) that fuel mitochondrial β-oxidation and ATP production.[26] To test whether ATG7-mediated autophagy governs this process, we tracked the intracellular fate of a fluorescent FA analogue, BODIPY C16, in *Atg7*$^{PT\text{-}KO}$ and control mPTCs (**Figure 4D**). Following a 24-hour pulse and 24-hour chase, control cells efficiently

mobilized Green-C16 from LDs to mitochondria, while the tracer remained trapped in LDs in *Atg7*$^{PT\text{-}KO}$ cells (**Figure 4E**), indicating impaired FA release and trafficking. Consistently, seahorse-based metabolic profiling revealed reduced basal respiration, mitochondrial ATP-linked respiration, and maximal oxygen consumption rates (OCRs) in mutant cells (**Figure 4F**), accompanied by decreased mitochondrial membrane potential (**Figures 4G and S10D**) and elevated mitochondrial reactive oxygen species (ROS; **Figures 4H and S10E**), despite unchanged levels of mitochondrial proteins and content (**Figure S10F**). To test whether pharmacological enhancement of lipid metabolism could restore PT cell-fate specialization and differentiation, we treated *Atg7*-deficient cells with fenofibrate, a PPARα agonist known to enhance cytosolic lipolysis and FAO pathways.[19] Fenofibrate induced expression of *Pnpla2*, *Lipe*, *Mgll*, *Cpt1*, and *Cpt2* (**Figures S11A-S11C**), rescued LD homeostasis without reversing autophagy defects, yet suppressed aberrant proliferation and rescued PT-specific gene expression, differentiation markers, and endocytic uptake in *Atg7*$^{PT\text{-}KO}$ cells (Figures S11D–S11H). Conversely, inhibition of mitochondrial FA import using etomoxir[27,28] in control cells mimicked ATG7 deficiency — leading to impaired ligand uptake and LD accumulation (**Figures S11H-S11I**). Together, these findings demonstrate that ATG7-dependent autophagy is essential for mobilizing LD-derived FAs to mitochondria, sustaining energy homeostasis, and supporting PT cell specialization. Importantly, enhancing lipid catabolism through PPARα activation can compensate for autophagy/lipophagy failure and restore core aspects of normal PT physiology.

Cell-autonomous role of ATG7 in PT metabolism and differentiation

To confirm the cell-autonomous role of ATG7, we cultured primary cells derived from microdissected PT segments of *Atg7*$^{fl/fl}$ kidneys and acutely deleted *Atg7* using adenoviral Cre-recombinase. This intervention effectively reduced *Atg7* mRNA and protein levels (**Figures 5A and S12A**) and impaired autophagy, as shown by decreased Map1lc3b-I to Map1lc3b-II conversion and reduced autophagosome formation under both fed and starved conditions (**Figures 5B and S12B**). Consistent with in vivo observations, *Atg7*-deleted

mPTCs accumulated lipid droplets (LDs) that failed to clear upon starvation or Bafilomycin A1 treatment, indicating defective lipophagy (**Figure 5C**). Following oleic acid overload and starvation in the presence/absence of BafA1(**Figure 5D**), these cells exhibited impaired autophagic delivery of LDs to lysosomes, evidenced by increased Plin2–Sqstm1 colocalization and reduced LipidTOX–LAMP1 colocalization (**Figure 5E**). Mitochondrial morphology and bioenergetic function were compromised (**Figures 5F and S12C**), accompanied by increased proliferation (**Figure 5G**), loss of PT-specific gene expression, enhanced dedifferentiation (**Figures 5H and S12D**), and impaired endocytic uptake (**Figures 5I and S12E-S12F**). Deletion of *Atg5* phenocopied these defects (**Figures S13A–S13E**), and loss of Fip200 — required for canonical autophagy but not for alternative trafficking pathways, such as LC3-associated phagocytosis (LAP[29]) and endocytosis (LANDO[30]) — similarly reduced ligand uptake (**Figures S13A-S13C, S13F-S13H**). Together, these findings demonstrate that ATG7-dependent autophagy acts in a cell-autonomous manner to coordinate metabolic fate, differentiation, and functional specialization in the kidney tubule epithelium.

Metabolic and functional conservation of ATG7 in nematodes and zebrafish

To evaluate the evolutionary conservation of ATG7 function, we examined autophagy and epithelial homeostasis in *Caenorhabditis elegans* and *Danio rerio* (zebrafish). In *C. elegans*, we employed two established reporters[31]: SQST-1::RFP to monitor autophagy flux and DHS-3::GFP to visualize intestinal LDs (**Figure 6A**). *atg-7* mutants showed increased SQST-1 accumulation (**Figure 6B**), elevated intestinal LD content (**Figure 6C**), and impaired mitochondrial bioenergetics, as reflected by reduced whole-organism oxygen consumption (**Figure 6D**).

The zebrafish pronephros mimics the mammalian kidney PT in structure and function, including reliance on endolysosomal trafficking, FAO, and receptor-mediated endocytosis.[32] We generated whole-body *atg7*-null zebrafish using CRISPR/Cas9 editing (**Figures S14A–S14C**). Although early development was unaffected (**Figure S14D**), *atg7*^{KO} larvae showed

reduced motility from 14 days post-fertilization (dpf) and increased mortality beyond 20 dpf (**Figures 7A–7C**). To visualize autophagy in vivo, we generated a transgenic zebrafish line expressing the autophagosome marker mCherry-MAP1LC3B (**Figure 7D**). In *atg7*-deficient larvae, autophagosome formation in the pronephros was significantly reduced (**Figures 7E and S14E**), a defect confirmed by electron microscopy showing aberrant phagophore structures and disrupted autophagic vacuoles (**Figure S14F**). To assess pronephric function, we utilized a low-molecular-weight proteinuria biosensor line (lfabp10a::½vdbp-mCherry).[33] At 14 dpf, *atg7*^{KO} larvae exhibited elevated urinary mCherry levels, indicative of tubular dysfunction and impaired reabsorption (**Figure 7G**). Expression of wild-type human ATG7 in *atg7*-deficient zebrafish rescued both pronephric function and LMW proteinuria (**Figures 7H and S14G–S14H**). Furthermore, pharmacological inhibition of mitochondrial FAO with non-toxic doses of etomoxir in wild-type larvae induced swimming defects and tubular proteinuria (**Figures 7I–7J**), phenocopying atg7 deficiency. Together, these data reveal that ATG7-dependent autophagy is an evolutionarily conserved mechanism critical for epithelial energy homeostasis and functional specialization across species.

Association of ATG7 variants with kidney function and human diseases

Our findings across multiple model systems highlight the essential role of ATG7 in sustaining proximal tubule (PT) homeostasis and functional specialization. While autophagy dysfunction has long been implicated in disease pathogenesis[5], direct associations between human *ATG7* variants and kidney phenotypes have remained elusive. To address this gap, we conducted a large-scale phenome-wide association study (PheWAS) using data from 635,969 individuals in the VA Million Veteran Program.[34] This analysis uncovered a genome-wide significant association ($p = 2 \times 10^{-11}$) with a rare intronic *ATG7* variant (rs375156407; MAF = 0.06%), linked to multiple kidney-related conditions (**Figures 8A and S15A-S15B**), suggesting a pathogenic or risk-modifying role for autophagy gene variants in human disease.[5,35] Further, analysis of Human Genetic Evidence (HuGE) scores from the Common Metabolic Diseases Knowledge Portal (https://md.hugeamp.org/) — which integrates

genome-wide association data across diverse populations and phenotypes — revealed associations between *ATG7* variants and numerous kidney-related traits, including blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR) by creatinine and cystatin C, and cardiometabolic traits known to influence kidney function, such as blood pressure regulation, hypertension, waist-hip ratio (a surrogate for visceral adiposity), and specific circulating lipid species, including TAGs (**Figure 8B**).

At the rare end of the allele frequency spectrum, ultra-rare biallelic ATG7 variants were recently reported in five families presenting with neurodevelopmental disorders.[21] Two adult female siblings (P1 and P2) from one family carried compound heterozygous loss-of-function variants (c.1975C>T [p.Arg659]; c.2080-2A>G, NM_006395.2), resulting in undetectable ATG7 protein in multiple tissues.[21] This prompted us to test whether a congenital lack of ATG7 in humans might also cause tubular proteinuria and kidney tubulopathy. While classical markers of tubular proteinuria (e.g., RBP, aminoaciduria) were absent in both siblings, P2 showed elevated urinary CC16 — a sensitive LMW PT dysfunction marker — compared to P1 and healthy controls (**Figure S16A**). Urine metabolomic profiling revealed distinct metabolic signatures in both siblings relative to controls (**Figures S16B-S16C**). Notably, P2 exhibited enrichment in pathways related to glucose, amino acid, and nucleotide metabolism, fatty acid degradation, the TCA cycle, and cancer metabolism (**Figure S16D**), paralleling the metabolic reprogramming observed in our ATG7-deficient preclinical models.

ATG7 impacts metabolism, differentiation and prognosis in renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC), the most prevalent form of kidney cancer, originates from proximal tubule (PT) cells and is characterized by lipid droplet (LD) accumulation.[36,37] Given the enrichment of cancer metabolism signatures and LD buildup observed in ATG7-deficient mouse PT cells (mPTCs) and human urine samples, we investigated the potential role of ATG7 in ccRCC. In the UK Biobank cohort (n = 394,841), predicted loss-of-function variants in *ATG7* were significantly associated with malignant neoplasms of the kidney (ICD-10 C64; $p = 2.16 \times 10^{-}$□, $\beta = 0.097$; **Figure S17A**). Consistently, analysis of The Cancer

Genome Atlas (TCGA-KIRC) revealed that ccRCC patients with the lowest tertile of *ATG7* expression had significantly worse overall survival compared to those with higher expression ($p = 0.022$; **Figure 9A**). To further explore this relationship, we conducted a meta-analysis of six transcriptomic datasets from ccRCC tumors[40] (656 tumors vs. 146 controls; **Figure 9B**). This analysis revealed coordinated upregulation of proliferation and dedifferentiation markers and downregulation of PT-specific genes (all combined $q < 0.001$, except *SOX9*; **Figure 9C**). Single-cell RNA sequencing (scRNA-seq) from two treatment-naïve ccRCC patients corroborated these findings, showing significantly reduced *ATG7* expression in *PAX8*$^+$ tumour cells compared to adjacent normal PT epithelia ($\log_2$ fold change = –1.20, $p = 0.05$; **Figure 9D**). Notably, the patient with the most pronounced *ATG7* downregulation also exhibited the highest tumour burden (**Figures S17B-S17C**). In tumour cells, this loss of *ATG7* was associated with activation of epithelial-to-mesenchymal transition (EMT) pathways, suppression of nutrient transporters, downregulation of mitochondrial metabolism, and loss of differentiation programs (**Figures S17D–S17E**), closely recapitulating the molecular phenotype of ATG7-deficient PT cells. Collectively, these data implicate ATG7 deficiency in promoting the lipid-rich, dedifferentiated, and proliferative phenotype characteristic of ccRCC, and position ATG7 as a prognostic marker and candidate therapeutic target in kidney cancer.

Discussion

Coordination of metabolism and differentiation is fundamental to tissue homeostasis and organ function. Here, we identify ATG7-dependent autophagy as a central regulator of epithelial cell fate in the proximal tubule of the kidney — a metabolically active structure responsible for selective nutrient reabsorption and transport. We demonstrate that ATG7 is essential for lipophagy and LD clearance, enabling the mobilization of FAs to mitochondria to support oxidative phosphorylation and fuel the energetic demands required for reabsorption and homeostatic functions (**Figure 10**).

Mechanistically, ATG7 deficiency—induced via genetic deletion in mice, adenoviral knockdown in primary cells, or CRISPR-based disruption in zebrafish—consistently led to LD accumulation, mitochondrial dysfunction, and a shift toward anabolic, proliferative states that compromise differentiation and receptor-mediated endocytosis. These phenotypes were recapitulated across models and linked to impaired cellular specialization. In humans, both rare coding variants and low *ATG7* expression levels were associated with cardiometabolic health, kidney function biomarkers, increased disease susceptibility, and poor prognosis in clear cell renal cell carcinoma (ccRCC), supporting the clinical relevance of this autophagy-dependent pathway (**Figure 10**). Collectively, our findings position ATG7 as a gatekeeper of metabolic fidelity and epithelial identity, and a promising therapeutic target for restoring kidney function in metabolic and kidney diseases.

In genetically engineered models, high-resolution imaging and functional analyses revealed that loss of ATG7 in PT cells results in the accumulation of damaged mitochondria and SQSTM1-positive protein aggregates — canonical markers of autophagy failure. This buildup of cellular stress triggers metabolic reprogramming and loss of reabsorptive capacity, culminating in urinary loss of essential proteins and solutes. Thus, beyond maintaining quality control,[41] ATG7-mediated autophagy orchestrates the balance between catabolic and anabolic flux to preserve PT cell identity and function.

Strikingly, ATG7-deficient murine PTs phenocopy key features of inherited proximal tubulopathies, including defective endocytosis, aberrant growth signalling, and reduced

expression of nutrient transporters and endocytic receptors.[2,6,7] In addition to canonical autophagy, ATG7 may also participate in non-canonical processes such as LC3-associated phagocytosis (LAP[29]) and LC3-associated endocytosis (LANDO[30]), raising the possibility that its role in epithelial specialization extends beyond classical autophagic pathways. Notably, loss of FIP200 — a core autophagy component essential for canonical autophagy but dispensable for LAP or LANDO — recapitulates the endocytic and differentiation defects observed in ATG7-deficient cells. This finding underscores that canonical autophagy, rather than noncanonical LC3 conjugation routes, is required for epithelial nutrient uptake and homeostasis. Supporting the evolutionary conservation of this role, zebrafish larvae lacking *atg7* exhibit hallmark features of autophagy-deficient mice[10,13] — including impaired motility, low molecular weight proteinuria, and early lethality. Remarkably, re-expression of human *ATG7* in mutant larvae rescues pronephric function and ameliorates proteinuria, further validating the central role of ATG7 in PT differentiation, energy balance, and kidney function across vertebrates.

How does loss of ATG7 compromise epithelial homeostasis and PT specialization? PT cells depend heavily on mitochondrial fatty acid oxidation (FAO) to fuel the reabsorptive and transport processes that maintain systemic nutrient balance.[17,19,20] Lipid droplets serve as a dynamic energy reservoir, releasing fatty acids (FAs) through both cytosolic lipolysis and autophagy-dependent degradation (lipophagy).[19,26,42] Through integrated multi-omics and functional validation, we show that ATG7 deficiency impairs lipophagy, thereby limiting FA release, reducing FAO and ATP production, and triggering mitochondrial dysfunction — evidenced by organelle fragmentation, membrane potential loss, oxidative stress, and impaired respiratory capacity. This energy shortfall induces a compensatory shift toward anabolic and proliferative programs at the expense of epithelial differentiation, ultimately manifesting as nutrient-wasting tubulopathy.

Lipid dysmetabolism and lipid droplet accumulation — whether from defective lipophagy or increased de novo lipogenesis — is a shared feature of metabolic and non-metabolic kidney diseases.[42] Spatial metabolomics of diseased human kidneys reveal

diminished FAO, lipid accumulation, and mitochondrial injury in PT cells, implicating disrupted lipid catabolism in pathogenesis.[42] Preclinical studies have shown that activation of lipid-catabolic regulators, including PPARα, ERRα, and CPT1A, mitigates kidney injury and fibrosis in chronic kidney disease (CKD) models.[42] In line with these findings, we show that pharmacologic activation of cytosolic lipolysis via the PPARα agonist fenofibrate restores mitochondrial energy metabolism and function, PT gene expression, receptor-mediated endocytosis, and structural features of differentiation — including primary cilia[43] — in ATG7-deficient cells, despite persistent autophagy impairment. These results define a conserved ATG7–lipophagy axis that integrates lipid turnover with mitochondrial energetics to instruct PT cell fate and function, positioning ATG7 as a metabolic switch governing epithelial specialization.

By linking lipid metabolism, autophagy, and epithelial cell fate commitment, our study provides broad insights into kidney physiology and systemic metabolic homeostasis. Integrative human genetic analyses — including genome- and phenome-wide association studies — reveal that common variants within the *ATG7* locus are associated with kidney function traits, cardiometabolic risk factors, and increased susceptibility to chronic kidney disease (CKD). Complementary longitudinal lipidomics profiling in over 91,000 individuals underscores the clinical relevance of dysregulated lipid metabolism, identifying elevated VLDL, cholesteryl esters, and triglycerides as early predictors of CKD onset and progression.[44] Moreover, clinical evaluation of individuals harbouring biallelic *ATG7* loss-of-function mutations uncovered mitochondrial dysfunction and subtle proximal tubule abnormalities — including low-level proteinuria — undetected by standard assays. These findings emphasize both the pathogenic potential of *ATG7* deficiency, the existence of alternative degradative pathways and/or yet-to-be-discovered compensatory mechanisms in humans,[45] and the limitations of current diagnostic tools, underscoring the need for more sensitive metabolic biomarkers in early disease detection.

Notably, *ATG7* downregulation also marks poor prognosis in clear cell renal cell carcinoma (ccRCC) — the most prevalent kidney cancer subtype arising from proximal

tubule (PT) cells and characterized by lipid droplet accumulation.[36,37] Across multiple transcriptomic datasets, low *ATG7* expression correlates with epithelial-to-mesenchymal transition, suppressed oxidative phosphorylation, and loss of PT differentiation programs — mirroring the metabolic and transcriptional rewiring observed in our *ATG7*-deficient models and inherited tubulopathies such as cystinosis.[6,7] These parallels support a unifying model in which *ATG7*-driven autophagy couples lipid turnover to mitochondrial bioenergetics to sustain epithelial identity and function. Disruption of this autophagy–lipid–energy axis not only drives PT dysfunction and kidney disease development but also enables metabolic reprogramming in ccRCC, revealing shared vulnerabilities across chronic kidney injury and tumorigenesis.[46]

In summary, we define an evolutionarily conserved mechanism whereby ATG7-dependent autophagy governs epithelial specialization by linking lipid catabolism to mitochondrial energy production. This genetic-metabolic axis refines our understanding of kidney physiology and pathogenesis and offers a conceptual and therapeutic framework for targeting metabolic dysregulation in kidney disease and cancer.

MATERIAL AND METHODS

Ethical compliance. All the animal experiments were approved by the Cantonal Veterinary Office Zurich (license no. ZH195/2020 and ZH139/2022) and performed following the guidelines of the University of Zurich.

Human studies. Patients with an established diagnosis of ATG7-related spinocerebellar ataxia (MIM #619422), i.e. with biallelic pathogenic *ATG7* variants were recruited (Family 1; ref. 21). Written informed consent was obtained from the parents of the siblings in the study and controls following the Declaration of Helsinki protocols, and the experimental protocol was approved by the local institutional review board. Urine samples were collected in the morning and kept at 4°C before it was frozen at -80 °C. For immunoblot analysis, the loading volume was indexed to creatinine to correct for variations in urine concentration. Urinary creatinine levels were measured using UniCel DxC 800 proSynchron (Beckman Coulter, Fullerton, CA, USA), according to manufacturer instructions.

Antibodies and reagents. The following antibodies were used in this study: rabbit anti-Atg7 (Sigma-Aldrich, A2856; 1:200); rabbit anti-Apg5l/Atg5 (Abcam, 108327, 1:500); mouse anti-AQP1(Abcam, ab9566, 1:400); mouse anti-AMPKα (Cell Signaling Technology, 2793; 1:500); rabbit anti-phospho-AMPKα (Thr172) (Cell Signaling Technology, 2535; 1:500); mouse anti-β-actin (Sigma-Aldrich, A5441, 1:1000); rabbit anti-cleaved caspase 3 (Cell Signaling Technology, 9662, 1:400); rabbit anti-caspase 3 (Cell Signaling Technology, 9661, 1:400); rabbit anti-phospho-4E-BP1 (Ser65; Cell Signaling Technology, 9451, 1:500); rabbit anti-4E-BP1 (Cell Signaling Technology, 9644, 1:500); rabbit anti-FIP200 (Cell Signaling Technology, 12436S, 1:200); sheep anti-Lrp2/megalin (1:1000) was kindly provided by P. Verroust and R. Kozyraki (INSERM, Paris, France); rabbit anti-Laminin gamma 1 (clone A5; Thermo Fisher Scientific, MA5-14649, 1:400); rat anti-LAMP1 (Santa Cruz Biotechnology, sc-19992, 1:1000); rabbit anti-LC3 (PM036, MBL, 1:200); rabbit anti-NCoR1 (Cell Signaling Technology, S9448S; 1:500); anti-PPARα (Abcam 126289: 1:500); mouse anti-PCNA (Dako,

M0879, 1:500); guinea pig anti-Plin2 (Progen, GP40; 1:100); anti-SDH (Abcam, ab14715, 1:500); anti-PDHA1 (Abcam, ab110334, 1:500); anti-VDAC1 (Cell Signaling Technology, 4866, 1:500); anti-COX IV (Abcam, ab14744, 1:500); anti-cytochrome *C* (Abcam, ab110325, 1:500); rabbit anti-Rab5 (Abcam, ab218624; 1:500); rabbit anti-Rab7 (Abcam, ab137029; 1:500); rabbit anti-S6 ribosomal protein (Cell Signaling Technology, 2217; 1:500); rabbit anti-phospho-S6 ribosomal protein (Ser235/236) (Cell Signaling Technology, 4858; 1:500); mouse anti-SQTM1 (Abcam, ab56416; 1:500); rabbit anti-SQTM1 (Abcam, ab109012; 1:400); mouse anti-transferrin receptor (H68.4; Thermo Fisher Scientific 13-6800; 1:400); anti-acetylated tubulin (Sigma Aldrich T7451; 1:400); rabbit anti-VDBP (Dako A/S , Glostrup Danmark A0021, 1:500); human anti-Transferrin (Dako, A0061; 1:500); mouse anti-TOM20 (Abcam; ab186735; 1:400); rabbit anti-uteroglobin (also known as CC16, Abcam, ab40873; 1:500); sheep anti-uromodulin (K90071C, Meridian Life Science Inc., Cincinnati, OH, USA; 1:300); donkey-anti rabbit IgG, cross-absorbed secondary antibody, Alexa Fluor 488 (Thermo Fischer Scientific, A10040, 1:400); goat-anti mouse IgG, cross-absorbed secondary antibody, Alexa Fluor 633 (Thermo Fischer Scientific, A21052, 1:400); goat-anti mouse IgG, cross-absorbed secondary antibody, Alexa Fluor 546 (Thermo Fischer Scientific, A11003, 1:400); goat-anti rat IgG, cross-absorbed secondary antibody, Alexa Fluor 633 (Thermo Fischer Scientific, A21094, 1:400); donkey-anti goat IgG, cross-absorbed secondary antibody, Alexa Fluor 633 (Thermo Fischer Scientific, A21094, 1:400); donkey-anti sheep IgG, cross-absorbed secondary antibody, Alexa Fluor 633 (Thermo Fischer Scientific, A21100, 1:400). Compounds included Bafilomycin A1 (BafA1; Enzo Life Sciences, ALX-380-030, 250 nM), the biotinylated Lotus Tetragonolobus Lectin (LTL; Vector Laboratories, B-1325), and 4′,6-diamino-2-phenylindole dihydrochloride (DAPI; D1306, Thermo Fischer Scientific; 1:1000), Etomoxir (Merck; 23620), and Fenofibrate (Sigma Aldrich; F620), PIK3C3/Vps34 inhibitor SAR-405 (A8883, APExBIO). All molecules were of at least 98% purity and dissolved in dimethylsulfoxide (DMSO) for experiments unless specified. BSA-conjugated oleic acid (OA; Cayman Chemical, 29557; 300 µM) was diluted in the culture

medium. The cells used in this study were negatively tested for mycoplasma contamination using MycoAlert™ Mycoplasma Detection Kit (LT07-118, Lonza, Switzerland).

***C. elegans* strain maintenance.** For all experiments using invertebrate *C. elegans*, hermaphroditic animals were used (wild-type and *atg7* mutant). Worms from mutant deletion strains were genotyped by PCR, and the PCR amplicon sizes were used to check for the presence of the deletion. The ages of adult animals are specifically defined in the figures and figure legends. The nematodes were raised at 20 °C on nematode growth medium (NGM) agar (51.3 mM NaCl, 0.25% peptone, 1.7% agar, 1 mM $CaCl_2$, 1 mM $MgSO_4$, 25 mM KPO_4 and 12.9 µM cholesterol, pH 6.0). Fed worms were maintained on NGM agar plates that had been seeded with *Escherichia coli* OP50 bacteria. Synchronous populations of worms were obtained by bleaching young adult hermaphrodites. Briefly, adult hermaphrodites were exposed to 1 mL bleaching solution (0.5 M NaOH and 20% bleach) for 5 min to isolate eggs, and eggs were then washed three times in M9 buffer (22 mM KH_2PO_4, 42 mM Na_2HPO_4, 85.5 mM NaCl and 1 M $MgSO_4$) before plating.

Quantification of lipid droplets and autophagy in *C. elegans*. To visualize LDs, we utilised a reporter strain expressing DHS-3 fused to GFP [LIU1: (N2; IdrIs1 (dhs-3p::dhs-3::GFP; unc-76+)], LRL262: [*atg-7(bp411)*; IdrIs1 (dhs-3p::dhs-3::GFP; unc-76+)], a well-established marker for LDs in *C. elegans*.[31] DHS-3 is orthologous to the mammalian 17β-HSD11 and is among the most abundant LD-associated proteins identified via mass spectrometry in *C. elegans*.[47] Its localisation to the LD membrane was confirmed through fluorescence microscopy. To visualise autophagy, we employed a reporter strain expressing SQST-1 fused to RFP [(LRL160: [N2; llcIs12 (p62p::p62::RFP::unc-54 3'UTR; myo-2::GFP)] and LRL256: [*atg-7(bp411);* llcIs12 (p62p::p62::RFP::unc-54 3'UTR; myo-2::GFP)], which is orthologous to the mammalian autophagy receptor SQSTM1/p62. Imaging was performed on day 3 or 4 of adulthood. Approximately 10 worms were imaged per condition for each experiment. Worms were mounted on a 2% agar pad, anaesthetised with 50 mM sodium

azide, and covered with a glass coverslip for imaging. Confocal images were captured using an Olympus Fluoview FV3000 microscope equipped with the FV316-SW software (version 2.3.2.169). A 60% oil objective (UPLAN 60x oil, 2.35NA Olympus, Japan) and a 1.90-µm pinhole (resulting in an optical section thickness of 2.2µm) were used. SQST-1::RFP reporter strain imaging was performed using a Zeiss V20 Discovery microscope equipped with an AxioCam 820 mono camera, Achromat S 1.0x FWD 63mm objective, and the Zeiss Zen 3.8 software. Imaging conditions, such as laser power and exposure time, were kept consistent across all samples. The mean fluorescence intensity was quantified using Fiji (version 2.0.0) by applying uniform thresholds to all images for consistency.

Oxygen consumption measurements in *C. elegans*. Worms were synchronized using a standard hypochlorite treatment protocol. Eggs were placed on OP50-seeded NGM plates and grown to day 2 of adulthood. Adult worms were hand-picked and transferred to P10 plates to control population density, with two plates containing 500 worms each and two plates containing 250 worms each. Worms were allowed to acclimate at 20°C for 30 minutes to minimize stress before measurements. Worms were harvested by rinsing the plates twice with 7 mL of M9 buffer, ensuring thorough collection. The suspensions were centrifuged at 1,000 rpm for 90 seconds, and the supernatant was discarded. Worms were washed three times with 13 mL of M9 buffer to eliminate residual bacteria and debris. After the final wash, 100µL of the worm suspension was transferred into a pre-calibrated Oroboros chamber using a Pasteur pipette, ensuring minimal loss and preventing worms from adhering to surfaces. Oxygen consumption was continuously monitored using the Oroboros O2k system. Measurements were recorded until the nematodes exhibited signs of mortality. Data were normalized to the initial number of worms introduced into the chamber. All analyses were conducted using DatLab software.

Generation and maintenance of *atg7* zebrafish. The pT7-gRNA and pT3TS-nCas9n plasmids were sourced from Addgene (#46759 and #46757, respectively). To monitor

CRISPR-Cas9-mediated mutations and facilitate genotyping, we selected the CRISPR-Cas9-targeted region (5′-GGCGAACTGAAGCTTCAGACTGG-3′), which contains the HindIII restriction site (AAGCTT). Oligonucleotides containing the sgRNA-targeting sequence were annealed and cloned into the Esp3I (BsmBI)-digested *pT7-gRNA* vector, resulting in *pT7-gRNA-atg7*. The oligonucleotide sequences were CRISPR-atg7-S: 5′-TTAGGCGAACTGAAGCTTCAGAC-3′ and CRISPR-atg7-AS: 5′-AAACGTCTGAAGCTTCAGTTCG-3′. Cas9 messenger RNA was produced by utilizing the XbaI-linearized *pT3TS-nCas9n* vector with the mMESSAGE T3 kit (Invitrogen). Both sgRNA-*atg7* and Cas9 mRNA were co-injected into one cell stage AB zebrafish embryos (*Danio rerio*). Genomic DNA was extracted from 2 dpf embryos that developed normally to detect CRISPR-Cas9-induced mutation. Mosaic AB embryos injected with CRISPR-Cas9 were raised to adulthood (F0) and outcrossed with wild-type AB zebrafish. The resulting embryos (F1) were raised to adulthood, and heterozygous carriers were screened. We identified a heterozygous carrier with the mutation of 6bp-deletion + 2bp insertion ($atg7^{+/del4}$), and subsequent generations (F1) were crossed to obtain homozygous mutants carrying $atg7^{del4/del4}$. The CAS-OFFinder analysis confirmed that there were no off-target edits in other genes. Zebrafish larvae (AB background) were maintained on a 14/10 h day/night cycle at 28°C and fed a standard diet (Zebrafeed 100-200, SPAROS, Portugal) from 5 dpf. Experiments were primarily conducted on larvae aged 5-14 dpf, with animal sex not specified at this developmental stage. Stable zebrafish lines expressing mCherry-tagged half vitamin D binding protein (½vdbp-mCherry) in the liver or hMAPLC3B in the kidney were established. These lines were subsequently outcrossed with $atg7^{+/del4}$ zebrafish to generate a transgenic mutant line. The latter was further crossed with $atg7^{+/del4}$ zebrafish to produce homozygous larvae. The measurement of ½vdbp-mCherry and mCherry-hMAPLC3B-flagged autophagic vesicles was assessed by ELISA and multiphoton microscopy, respectively.

Complementation studies in zebrafish. For the generation of transgenic lines with a proximal tubule-specific expression of human *ATG7*, multisite Gateway cloning technology was used to generate the expression vector *PiT1::EGFP-hATG7* using plasmids coming from Tol2 kit v1.2. The cloning of the promoter of the zebrafish phosphate transporter 1/*slc20a1a* (*p5E-PiT1*) genes was previously described.[6,7] Human *ATG7* cDNA was amplified from the vector *pCMV-myc-ATG7* (kindly provided by Toren Finkel (Addgene plasmid # 24921)) and subcloned into the *pENTR/D-TOPO vector* (Invitrogen) after N-Terminal Tagging with EGFP. The final expression vector *PiT1::EGFP-hATG7* was realized after LR Reaction (Gateway LR Clonase II Enzyme Mix, Invitrogen), which utilizes the LR Clonase for vector construction through plasmids *p5E-PiT1*, *pED-EGFP-hATG7*, *p3E-polyA* and destination vector *pDestTol2CG2* with *cmlc2::EGFP* transgenesis marker. Plasmid DNA of *PiT1::EGFP-hATG7* vector was co-injected with Tol2 transposase mRNA into zebrafish embryo at the one-cell stage to generate a stable transgenic line. Zebrafish *atg7*$^{+/del4}$, *Tg(PiT1::EGFP-hATG7)* was generated after crossing the *Tg(PiT1::EGFP-hATG7)* with *atg7* mutant zebrafish. For the rescue of LMW proteinuria, *atg7*$^{+/del4}$, *Tg(PiT1::EGFP-hATG7)* was crossed with *atg7*$^{+/del4}$, *Tg(lfabp::½vdbp-mCherry)* to produce double transgenic *atg7*^{WT} and *atg7*^{KO}larvae. Overnight urine collection was performed at 10 and 14dpf for ELISA assay following the protocol described below.

Swimming behaviour. The movement tracking of zebrafish larvae was conducted using a custom-built setup, comprising a projector (HP vp6111) for background light, an infrared light source for camera-tracking, and a high-speed camera (Allied Vision Stingray) equipped with a Fujinon 1:1.4/12.5mm objective (Fujinon). Both tracking and background light control were executed through the open-source tracking software Stytra. In each experiment, up to 10 larvae were situated in a specially designed arena featuring 10 lanes (1cm width x 16cm length), all filled with E3 medium. The tracking process involved monitoring larval swimming distances along each lane over 5 minutes. Larval identity was established by tracing a

Region of Interest (ROI) on each lane, and the distance covered was calculated by summing the distances between each consecutive coordinate.

Zebrafish urine collection and mCherry measurements. Zebrafish larvae (AB background) were placed in a 48-well microplate with one larva/500 mL facility water/well and kept at 28°C for 16 hours, followed by urine collection for ELISA assay. The levels of ½vdbp-mCherry were measured according to the manufacturer's protocol. Briefly, 50 μl of fish pool water containing urine was distributed to a 96-well microplate pre-coated with anti-mCherry antibody. A 50 μL mixture of capture antibody and detector antibody was added to each well and incubated at room temperature for 1 hour. The wells were rinsed three times with washing buffer and incubated with 100 μL of TMB development solution at room temperature for 10 minutes. The reaction was stopped by adding 100μl of stop solution, followed by reading the absorbance of each well at 450 nm.

Mouse models. The mouse lines were used: *Fip200*$^{fl/fl}$, *Atg5*$^{fl/fl}$, *Atg7*$^{fl/fl}$ and *γGt1*-Cre. The *Fip200*$^{fl/fl}$ and *Atg5*$^{fl/fl}$ mouse lines were kindly provided by Dr. C. Münz (University of Zurich). The *Atg7*$^{fl/fl}$ mice[10] (C57BL/6J background) were obtained from the RIKEN repository (National BioResource Project, started by the Ministry for Education, Culture Sports, Science and Technology, Japan). The *Atg7*$^{fl/fl}$ mice were generated by inserting two Lox P sites around exon 14, which encodes the active site cysteine essential for activation of the conjugation substrates. The Cre-expressing mouse line was obtained from The Jackson Laboratory (RRID: IMSR_JAX:012841). The rat proximal promoter to γ*Gt1* was used in a transgene construct to drive Cre recombinase expression.[22] The γ*Gt1-Cre* promoter becomes active around postpartum day 14, coinciding with the completion of nephrogenesis and thus targeting cortical tubular epithelium in mature kidneys.[22] The Cre-expressing mice (C57BL/6 x SJL background) were backcrossed (>10 times) into the C57BL/6 background. The PT-specific *Atg7*^{KO} mice were generated by crossing mice carrying the respective LoxP-

flanked alleles with *γGt1*-Cre transgenic mice. All mice were housed at the animal service centre of the University of Zurich under specific pathogen-free conditions and maintained under controlled temperature (22-25°C) and humidity (50-60%), with 12-h dark/light cycle and ad libitum access to tap water and standard chow (Diet AO3, SAFE). Kidneys were collected for analysis at the time of sacrifice. Both female and male mice at 4, 12, and 24 weeks of age were used for kidney function studies, whereas the other experiments were performed using mice at 12 and 24 weeks of age. Littermates not carrying the *γGt1-Cre* transgenes were used as controls in all experiments.

Kidney function and metabolic parameters. The mice were placed overnight in metabolic cages with ad libitum access to food and drinking water; urine was collected on ice, and body weight, water intake and diuresis were measured. Blood (from a sublingual vein) was obtained after anaesthesia with ketamine/xylazine or isoflurane. Urine and blood parameters were estimated using UniCel DxC 800 proSynchron (Beckman Coulter, Fullerton, CA, USA). Urinary levels of low-molecular-weight CC16 were measured by using an ELISA according to the manufacturer's instructions (BIOMATIK EKU03200, Thermo Fischer Scientific, Waltham, MA). Albuminuria was measured via Coomassie Blue staining by using ProtoBlue Safe (National Diagnostics, EC-722, Atlanta, GA, USA) according to the manufacturer's instructions.

Amino acid measurements in the urine. Urinary amino acid concentrations were measured at the Functional Genomic Center Zurich, University of Zurich, using liquid chromatography-mass spectrometry (LC-MS/MS). Before injection, 50µL of urine was mixed with 10% sulfosalicylic acid, precipitated, and centrifuged for 10 minutes at 12000 rpm. The supernatant was then mixed with 30µL borate buffer, 5µL 500µM MSK-CAA-1 internal standard, and 10µL AQC solution, totalling 50µL. After a 10-minute incubation at 55°C, samples were loaded onto a Waters UPLC H-Class Plus system with an Acquity PLC Quadrupole Solvent Manager and Sample Manager. Derivatized amino acids were detected

using a Waters Qda single quadrupole mass detector in positive mode with selected ion monitoring (SIR). The column was maintained at 55°C, and 1µL was injected. Gradient elution used 0.1% formic acid in water (eluent A) and in acetonitrile (eluent B) with a constant flow rate of 0.5 mL/min and the following gradient for solvent B: Initial: 1%, 0.0-1 min: 1%, 1-4 min: 13%, 4-8.5 min: 15%, 8.5-9.5 min: 95%, 9.5-11.5 min: 95%, 12-15 min: 1%. Data were analyzed using Masslynx 4.2 (Waters).

Isolation of PT segments from mouse kidneys and primary cell cultures. Kidneys were harvested from Atg7$^{PT\text{-}KO}$ mice and their control littermates or from *Atg5*$^{floxed/floxed}$, *Atg7*$^{floxed/floxed}$, and *Fip200*$^{floxed/floxed}$ mice. One kidney was split transversally; one half was fixed and processed for immunostaining, and the other half was flash-frozen, homogenized in 1mL of RIPA buffer with protease and phosphatase inhibitors, and processed for western blot analysis. The contralateral kidney was used to generate primary cultures of mPTCs. Freshly microdissected PT segments were seeded onto chamber slides and/or 6- or 24-well plates and cultured at 37°C and 5% CO2 in DMEM/F12 with 0.5% dialyzed FBS, 15mM HEPES, 0.55mM sodium pyruvate, 0.1ml L^{-1} non-essential amino acids, hydrocortisone, human EGF, epinephrine, insulin, triiodothyronine, TF, and gentamicin/amphotericin, pH 7.40, 325mOsm kg^{-1}. The medium was replaced every 48 hours. Confluent monolayers of mPTCs, expanded from the tubular fragments after 6-7 days, were characterized by a high endocytic uptake capacity and tested negative for mycoplasma contamination.

Nutrient starvation protocols and cellular treatments. The withdrawal of serum, glucose, and amino acids was achieved by washing mPTCs with Hank's balanced salt solution and placing them in either a normal growth or nutrient-deprived medium for the indicated times. Lysosomal proteolysis was inhibited, where indicated, by adding BafA1 (250nM in cell culture medium for 4 hours). The cells were then processed and analysed as described below.

Adenovirus transduction. For expression studies, adenoviral constructs included a CMV control vector (Ad-CMV-GFP; #1060) and a vector carrying Cre-recombinase (Ad-Cre-GFP; #1700), both purchased from Vector Biolabs (University City Science Center, Philadelphia, USA). Adenovirus transduction was performed 24 hours after plating when the cells reached 70–80% confluence. Cells were incubated for 6 hours at 37°C with a culture medium containing the virus at a concentration of 20 x 10^5 PFU/ml. Fresh culture medium was exchanged every 2 days, and the cells were cultured for 3 days before being collected for analysis.

Proteomics

Sample preparation. Cell pellets (~5×10^5 cells; n = 4 mice/group) were lysed in 100 µL buffer, sonicated with HIFU (1 min, 85% amplitude), and heated at 95°C for 10 min. Proteins were further extracted using a Tissue Lyser II (2 × 2 min at 30 Hz), heated again for 10 min, and subjected to an additional 1-min HIFU. After centrifugation (20,000 × g, 10 min), protein concentration was measured with a Lunatic instrument. Fifty micrograms of protein per sample was digested by adding 10 µL “Digest” solution and incubating at 37°C for 60 min; digestion was stopped with 100 µL Stop solution. The mixture was filtered (3,800 × g), and peptides were washed, eluted, dried, and reconstituted in 40µL of 3% acetonitrile/0.1% FA with 1µL iRT peptides (1:100 dilution).

Liquid chromatography-mass spectrometry analysis. Peptides were analyzed on an Orbitrap Fusion Lumos (Thermo Scientific) with a Digital PicoView source (New Objective) and an M-Class UPLC (Waters). Solvent A was 0.1% FA; Solvent B was 0.1% FA in 99.9% acetonitrile. One microliter of peptides was loaded onto an MZ Symmetry C18 Trap Column (100 Å, 5 µm, 180 µm × 20 mm) and separated on a nanoEase MZ C18 HSS T3 Column (100 Å, 1.8 µm, 75 µm × 250 mm). The elution gradient was: 5% B for 3 min, 5–22% B over 80 min, 22–32% B over 10 min, then washed at 95% B for 10 min and re-equilibrated for 10 min. Samples were run in randomized order. The instrument acquired full-scan MS spectra (m/z 300–1,500) at 120,000 resolution (target 500,000 ions) and data-dependent MS/MS in

the ion trap (quadrupole isolation at 0.8 Da, HCD at 35% energy, target 10,000 ions, max 50ms injection time). Only precursors >5,000 intensity were selected (cycle time 3 s); charge states 1, unassigned, and >7 were excluded, with dynamic exclusion set to 20 s (10 ppm). Internal lock masses were m/z 371.1012 and 445.1200.

Protein identification and label-free protein quantification. Raw data were processed with MaxQuant (v1.6.2.3) using Andromeda against the SwissProt canonical mouse proteome (2019-07-09), its reversed decoy, and common contaminants. Fixed modification was carbamidomethylation (C); variable modifications were methionine oxidation and N-terminal acetylation. Trypsin/P was used, allowing peptides ≥7 amino acids with up to 2 missed cleavages. FDR was set to 1% for peptides and 5% for proteins. Label-free quantification was enabled with a 2-minute match-between-runs window, and each file was processed separately for individual quantification. Protein fold changes were calculated from Intensity values in the proteinGroups.txt file, filtering for proteins with ≥2 peptides and ≤3 missing values. Data were normalized via a modified robust z-score, and p-values were computed using a pooled variance t-test. For proteins missing all measurements in one condition, a pseudo–fold change was calculated using the mean of the lowest 10% intensities. Finally, pathway analysis was performed with Network Analyst (http://www.networkanalyst.ca) on significantly changed proteins in mPTCs from *Atg7* mouse kidneys.

Metabolomics

Urine metabolite extraction and LC-MS analysis

Extraction. Twenty microliters of creatinine-normalized urine were mixed with 80 µL of pre-cooled methanol. The mixture was incubated at –20°C for 1 h, then centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant was transferred to a clean test tube, dried under a nitrogen stream, and reconstituted in an injection buffer (90% acetonitrile). Following a second vortex and centrifugation (10,000 rpm, 4°C, 10 min), the clear supernatant was transferred to Total Recovery Vials (Waters) for LC-MS injection. Method blanks, standard mixes, and pooled samples were prepared identically to serve as quality controls.

LC-MS Data Acquisition. Urine metabolites were separated using a Thermo Vanquish Horizon Binary Pump equipped with a Waters Premier BEH Amide column (150 mm × 2.1 mm). A gradient was applied using solvent A (10 mM ammonium bicarbonate in 5% acetonitrile, pH 9.0) and solvent B (10 mM ammonium bicarbonate in 95% acetonitrile), transitioning from 99% B to 30% B over 12 min. The injection volume was 3.5 µL, with a flow rate of 0.4µL/min; the column was maintained at 40°C and the autosampler at 5°C. The LC was coupled via a HESI source to a Thermo Q Exactive mass spectrometer. MS1 and MS2 data were acquired in negative ion mode using Full MS/dd-MS^2 (Top5) over a mass range of 70–1050 m/z, at a resolution of 70,000 for MS1 and >17,500 for MS2. Quality controls were performed using pooled samples, reference compound mixtures, and blanks to assess technical accuracy and stability.

Untargeted Metabolomics Data Analysis. Data were processed with Compound Discoverer (Thermo Scientific) in an untargeted workflow that included spectral selection, retention time alignment, compound detection and grouping, gap filling, background filtering, and constant median normalization. MS2-based identities were assigned by scoring fragmentation patterns against the mzCloud and mzVault databases. A filtering process then generated a manually annotated compound table, with features assigned the highest level of confidence based on the following criteria: signal-to-noise ratio > 3, mzCloud or mzVault match score > 50, mass error within ±5 ppm, match to an in-house MS1_RT library within ±10 sec, and acceptable chromatographic peak and MS2 spectral quality.

Cellular metabolite extraction and LC-MS analysis

Sample Preparation. Cellular metabolism was quenched by adding 80% pre-cooled methanol to the cells. After vortexing, samples were incubated at –20°C for 1.5 h. Proteins were precipitated by centrifuging at 10,000 rpm for 20 min at 4°C, and the clear supernatant was transferred to a new vial. The supernatant was then dried under a nitrogen stream and reconstituted in 20 µL water mixed with 80 µL injection buffer (90% acetonitrile, 8.8% methanol, 50 mM ammonium acetate, pH 7). Following another round of vortexing and

centrifugation (10,000 rpm, 4°C, 10 min), the clear supernatant was transferred to Total Recovery Vials (Waters) for LC-MS injection. Method blanks, standard mixes, and pooled samples were prepared identically for quality control.

LC-MS Data Acquisition. Cell metabolites were separated using a Waters nanoAcquity UPLC with a BEH Amide capillary column (150 µm × 50 µm × 1.7 µm). A gradient was applied using solvent A (5 mM ammonium acetate in water) and solvent B (5 mM ammonium acetate in acetonitrile), transitioning from 5% A to 50% A over 12 min. The injection volume was 1µL, with the flow rate adjusted from 3 to 2 µL/min. The UPLC was coupled to a Waters Synapt G2Si mass spectrometer via a nanoESI source. MS1 and MS2 data were acquired in negative ion mode using MSE over a mass range of 50 to 1200 m/z at resolutions greater than 20,000.

Untargeted Metabolomics Data Analysis. Data were processed using Progenesis QI (Nonlinear Dynamics, Waters). Ion intensity maps were aligned to a reference dataset, and peak picking was performed on an aggregated map. Ions were identified by comparing accurate mass, adduct patterns, and isotope distributions with the Human Metabolome Database (HMDB) using a mass accuracy tolerance of 5 mDa; fragmentation patterns were also considered. All biological samples were analyzed in triplicate, with quality controls run on pooled samples and reference compound mixtures. Finally, pathway analysis of significantly altered metabolites in cells and urine samples was performed using MetaboAnalyst (http://www.metaboanalyst.ca) with default settings.

Lipidomics

Extraction: Lipid extraction was performed following a previously described method[48], with some modifications. A mixture of 1000 µL isopropanol: methanol (1:1) was added to each cell culture well. The plates were then incubated at -80 °C for 10 minutes. After incubation, the cells were scraped, and the resulting solution was transferred to Eppendorf tubes.
The samples were continuously mixed in a thermomixer (Eppendorf) at 25 °C (950 rpm) for 30 minutes. Protein precipitation was achieved by centrifugation at 16,000 g for 10 minutes

at 25 °C. The resulting single-phase supernatant was collected, dried under nitrogen (N_2), and stored at -20 °C until further analysis. Before analysis, the dried lipids were reconstituted in 100 µL methanol: isopropanol (1:1).

LC-MS analysis: The lipidomics LC-MS method was performed as previously described, with some modification.[48] A Waters Premier BEH C18 column (50µm × 2.1µm × 1.7µm) was used at 60°C for LC separation on a Thermo Vanquish Horizon tandem LC system. The injection volume was 2µL in positive mode and 5µL in negative mode, with a flow rate of 1 mL/min. A segmented gradient was applied, transitioning from 15% Buffer B to 99% Buffer B over a total gradient length of 7.5 minutes. The gradient segments were as follows: 0.0-1.0 min; 15-30%B,1.0-1.25 min; 30-48%B,1.25-5.0 min;48-82%B, 5.5-5.75; 82-99%B,5.75-6.0 min; isocratic at 99 %B,6.0-6.05; 99-15%B, 6.05-7.5; isocratic at 15%B. For the MS method, a Thermo Exploris 480 instrument was used in data-dependent acquisition mode (DDA) with top 5. Heated electrospray ionization (HESI) was used in positive and negative polarities in separate runs (sheath gas = 30, auxiliary gas = 13, spray voltage = 3800 and -3500 V, in positive and negative modes respectively), vaporizer temperature= 350C and ion transfer tube temp = 300°C). Internal mass calibration was used at the start of each run, and mild trapping was set to true to minimize in-source fragmentation (after the ion funnel). MS1 settings were as follows: resolution, 60000, scan range (150-2000 m/z), AGC target (1e6), max. Injection time (10ms). MS2 scan settings were as follows: isolation window (1 m/z), the stepped normalized collision energy was set to 10, 30, and 340 NCE %, Resolution = 15000, max injection time (10msec), AGC target (1e5), RF lens = 50%.

Data analysis: Data analysis was performed using Thermo Compound Discoverer software (version 3.3). Lipid identification was conducted by matching spectra against the LipidBlast library, followed by visual inspection of mirror plots (library vs. data) to confirm spectral alignment and the presence of diagnostic fragments. Identification was validated according to the Lipid Standards Initiative guidelines, ensuring compliance with established fragmentation rules. Only lipids that met the criteria for expected fragmentation spectra, mass accuracy threshold, and retention time (RT) pattern were included in the analysis.

Peak areas were normalized using median normalization, and statistical comparisons between groups were performed using a t-test after log transformation. Volcano plots and heatmaps were generated in R using the ggplot2 and ComplexHeatmap packages.

RNA isolation, reverse transcription, and quantitative PCR. Total RNA was extracted from mouse tissues or zebrafish larvae using the AurumTM Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA). To eliminate genomic DNA contamination, DNAse I treatment was performed. Total RNA was then extracted with an RNAqueousR kit (Applied Biosystems, Life Technologies). For cDNA synthesis, 1 µg of RNA was used with the iScript TM cDNA Synthesis Kit (Bio-Rad). Changes in mRNA levels of target genes were determined by relative RT-qPCR using a CFX96TM Real-Time PCR Detection System (Bio-Rad) and iQ TM SYBR Green Supermix (Bio-Rad). Analyses were performed in duplicate with 100nM of both sense and antisense primers in a final volume of 20 µL using iQTM SYBR Green Supermix (Bio-Rad). Specific primers were designed using Primer 3 (**Tables S3 and S4**). PCR conditions were 95°C for 3 min, followed by 40 cycles of 15 sec at 95°C and 30 sec at 60°C. PCR products were sequenced with the BigDye terminator kit (Perkin Elmer Applied Biosystems) using the ABI3100 capillary sequencer (Perkin Elmer Applied Biosystems). Primer efficiency was determined by dilution curves. The program geNorm version 3.4 was used to assess the expression stability of candidate reference genes in kidneys, and six reference genes were selected to calculate the normalization factor. Relative changes in targeted gene expression compared to *Hprt*, *Gapdh*, *Actb*, or *eef1a1a* mRNAs were calculated using the $2^{-\Delta\Delta Ct}$ formula.

Endocytosis assays in mouse kidneys and cultured primary PT cells.

Mouse kidneys. Receptor-mediated endocytosis and fluid-phase endocytosis were monitored in the PT segments of mouse kidneys by measuring the uptake of β-lactoglobulin (L3908, Sigma) and Alexa 647-conjugated dextran (D22914, Thermo Fisher Scientific), respectively. β-lactoglobulin was labelled with Cy5 using a TM2 Ab labelling kit (Amersham)

according to the manufacturer's instructions. Fifteen minutes after tail-vein injection of Cy5-β-lactoglobulin (0.8 mg/kg BW) or Alexa 647-conjugated dextran (1.2 mg/kg BW), all mice were anaesthetized, and their kidneys were harvested and processed for confocal microscopy.

Primary cells. Endocytic uptake was monitored in mPTCs by incubating them for 60 minutes at 4°C with specific markers: 20µg/mL BSA-Alexa-Fluor-647 (A34785, Thermo Fisher Scientific), 40µg/mL Lysozyme-647 (provided by Dr. A. Hall, University of Zurich), or 20µg/mL Dextran-Alexa-Fluor-647 (Invitrogen, D22914) in complete HEPES-buffered Dulbecco's modified Eagle's medium. After incubation, the cells underwent an acid wash and were warmed to 37°C in a growth medium for 20 minutes before fixation and processing for immunofluorescence analysis.

Lysosomal degradation. The detection of lysosomal activity was performed in mPTCs by using Bodipy-FL-Pepstatin A (P12271, Thermo Fischer Scientific) to the manufacturer's specifications. The cells were pulsed with 1µM Bodipy-FL-Pepstatin A in a Live Cell Imaging medium for 1h at 37°C, fixed and subsequently analyzed by confocal microscopy.

Imaging of LDs and pulse-chase experiments. Cells were incubated for 30 min with 2.5µM BODIPY 493/503 (D3922, Thermo Fisher Scientific) the staining solution prepared in a growth medium. The cells were washed 3 times in PBS, fixed in 4% PFA for 10 min, stained with DAPI for another 5 min, washed in PBS, and mounted in a drop of Prolong® Gold (P36934, Thermo Fisher Scientific). For pulse-chase experiments, palmitate (C16) was conjugated to BSA following the standard protocol from Seahorse Biosciences. BODIPY (D3821, Thermo Fisher Scientific) and PAL were conjugated in a 0.1% FA-free bovine serum albumin solution for 30 min at 37°C. Cells were incubated with 0.5µM BODIPY-PAL for 24 hours and chased in a growth medium for 24 hours. The cells were washed 3 times in PBS, fixed in 4% PFA for 10 min, immunolabelled with a mitochondrial marker (TOMM20) and stained with DAPI, and analysed by confocal microscopy. HCS LipidTOX™ (H34477,

Thermo Fisher Scientific) was used for LD staining. Cells were fixed in 4% PFA for 10 min, stained with DAPI for another 5 min, washed in PBS, and incubated in the dark with HCS LipidTOX™ (1:250) diluted in PBS for 45 min. For pulse-chase experiments, cells were incubated for 5 h with 300 µM OA diluted in culture medium and then chased in starvation medium (RPMI containing 0.1 % FBS) for 16 h in presence of BfnA1(250 nM for 4h) or not. Cells were washed fixed in 4% PFA for 10 min, immunolabelled with an autophagic (Sqstm1) or lysosomal (Lamp1) marker, stained with HCS LipidTOX™ (1:250) for 45 min in the dark and analysed by confocal microscopy.

Quantification of mitochondrial membrane potential and oxidative stress. Mitochondrial membrane potential (Δψ) was assessed following the manufacturer's guidelines. Cells were treated with 50 nM Tetramethylrhodamine Methyl Ester Perchlorate (TMRM, T668, Thermo Fisher Scientific) and 1µM MitoTracker Red FM (Invitrogen, M22426) during a 30-minute live cell imaging session at 37°C. After washing, cells were analyzed using confocal microscopy (Leica SP8, Center for Microscopy and Image Analysis, University of Zurich) within a chamber maintained at 37°C and 5% CO2. Fluorescence intensity was quantified using the open-source image processing software Fiji (ImageJ, NIH), as described below.

Immunofluorescence and confocal microscopy

*Mouse tissue slides***.** Fresh mouse kidneys were fixed by perfusion with 50-60 mL of 4% PFA (158127, Sigma-Aldrich), followed by dehydration and embedding in paraffin at 58°C. Paraffin blocks were sectioned into consecutive 5 µm-thick slices using a Leica RM2255 rotary microtome (Thermo-Fisher Scientific) on Superfrost Plus glass slides (Thermo-Fisher Scientific). Before staining, slides were deparaffinized in Xylenes (534056, Sigma-Aldrich) and rehydrated. Antigen retrieval was performed by heating the slides at 95°C for 10 min in a 10 mM sodium citrate buffer (pH 6.0). Slides were then quenched with 50 mM NH4Cl, blocked with 3% BSA in PBS Ca/Mg (D1283, Sigma-Aldrich) for 30 min, and incubated with primary antibodies diluted in blocking buffer overnight at 4°C. After two washes in 0.1%

Tween 20 (v/v in PBS), slides were incubated with fluorophore-conjugated Alexa secondary antibodies (Invitrogen) diluted in a blocking buffer at room temperature for 1 hour. They were subsequently counterstained with 1µg Biotinylated Lotus Tetragonolobus Lectin (LTL; B-1325, Vector Laboratories) and 1µM 4',6-Diamino-2-phenylindole dihydrochloride (DAPI; D1306, Thermo Fisher Scientific). Slides were mounted in Prolong Gold Anti-fade reagent (P36930, Thermo Fisher Scientific) and analysed by confocal microscopy using a Leica SP8 confocal laser scanning microscope (Center for Microscopy and Image Analysis, University of Zurich).

Primary cultured cells. The cells were fixed for 10 minutes with 4% PFAin PBS, quenched with 50 mM NH_4Cl, and permeabilized for 20 minutes in a blocking buffer solution (pH 7.4) containing 15 mM glycine (Carl Roth, 3908.2), 0.05% saponin (Sigma-Aldrich 47,036), 0.5% BSA (Carl Roth, 1ET6.3), 50 mM NH_4Cl (Sigma-Aldrich, A9734) dissolved in PBS. Subsequently, cells were incubated overnight with the appropriate primary antibodies at 4°C. After repeated washing with PBS, the slides were incubated for 45 minutes with the suitable fluorophore-conjugated Alexa secondary antibodies (Invitrogen), counterstained with 1µM DAPI for 5 minutes, mounted with Prolong Gold Anti-fade reagent, and analyzed using a Leica SP8 confocal laser scanning microscope or a Zeiss LSM 980 confocal laser-scanning microscope equipped with an Airyscan 2 multiplex system (Center for Microscopy and Image Analysis, University of Zurich).

*Image processing and quantification***.** Images were acquired with a Leica APO 63x NA 1.4 oil immersion objective at a resolution of 1,024 x 1,024 pixels or a Zeiss 63x 1.40 oil immersion objective with a resolution of 3,072 x 3,072 pixels. Micrographs were processed using Adobe Photoshop CS5 software (Adobe Systems Inc., San Jose, USA). Quantitative image analysis involved selecting randomly 5-10 visual fields per slide containing at least 3-5 proximal tubules (LTL-positive or AQP1-positive as indicated) or 10-15 cells.

Setting parameters were consistently applied across analyses, including pinhole size, laser power, and offset gain, ensuring detector amplification remained below pixel saturation. Subcellular structure analyses were performed using the open-source software CellProfiler[49],

specifically utilising the "Measure-Object-Intensity-Distribution" module to quantify the number of LD, Pepstatin A- and Map1Lc3b- or Sqstm1- or BSA- or Lysozyme-positive structures. For measurements such as tubular height in mouse kidneys, mitochondrial morphology, and mitochondrial membrane potential, image analysis was carried out using Fiji v.2.0.0 (ImageJ, NIH). For the quantification of colocalization, images were imported into FIJI v.2.0.0-rc-69/1.52i, and individual channels were thresholded independently to eliminate background. Colocalization was assessed on individual cells with the JACOP plugin and Mander's coefficients. The number of cells and/or fields of view used per condition and the number of biologically independent experiments are indicated in the figure legends.

Imaging of zebrafish larvae. Quantitative analysis of fluorescent signals involved examining an entire pronephric tubule from each zebrafish larva, maintaining consistent setting parameters throughout the process. A multi-photon fluorescence microscope (Leica SP8 MP DIVE Falcon; Leica Microsystems, Heerbrugg, Switzerland) equipped with a 25/1.0 NA water immersion objective (HC IRAPO L, Leica) was used for capturing high-resolution images. The excitation wavelength was generated by a 1040 nm tunable laser for mCherry imaging. A light sheet fluorescence microscope (ZEISS Light sheet Z.1, Carl Zeiss Microscopy, Jena, Germany) equipped with a 20×/1.0 NA water immersion objective (W Plan APO, Zeiss) was used for detecting the human EGFP-ATG7 in mutant zebrafish larvae.

Data acquired underwent processing with Huygens software (Scientific Volume Imaging, Hilversum, The Netherlands) for deconvolution, followed by segmentation using Ilastik software (EMBL, Heidelberg, Germany). Quantitative analysis of fluorescence intensity, vesicle number, and vesicle area in each image stack was conducted using Fiji (ImageJ, NIH), an open-source image processing software. For the segmentation of Map1Lc3b spots, image stacks were analysed using the object analyzer plugin within Huygens. This involved setting seed and threshold levels using algorithms, employing watershed segmentation, and filtering objects to isolate Map1Lc3b spots. A lower threshold was established to identify the entire kidney volume as a single object. The number of spots and extracted morphological parameters (such as length, volume, and sphericity) were exported in Excel format for

subsequent statistical analysis. Surface images generated were used to create 3D volume-rendering images for visualisation purposes.

Immunohistochemistry. Paraffin kidney sections were rehydrated, and antigen retrieval was performed either by heat-induced treatment in 10 mM sodium citrate buffer with 0.05% Tween-20 at pH 6.2 or by proteinase K treatment. Endogenous peroxidase activity was blocked using a peroxidase-blocking buffer for 15 minutes at room temperature. Sections were then blocked in a solution containing 1% BSA, 0.2% fish-skin gelatine, 0.2% Triton-X-100, and 0.05% Tween-20 in PBS for 1 hour at room temperature. Following blocking, sections were incubated overnight at 4°C with a primary antibody against Cre (Cell Signaling 15036S, 1:200). The next day, sections were incubated with biotinylated anti-mouse IgG (H+L) secondary antibody (Vector Laboratories, BA-9200- 1.5, diluted 1:1,000) or anti-Rabbit secondary antibody. Each staining was visualized using the ABC Kit Vectastain Elite (Vector, PK6100) and DAB substrate (Dako and Vector Laboratories).

Histology and semiquantitative analysis of fibrosis. Picrosirius red staining (ab150681, Abcam, Cambridge, UK) was performed following the manufacturer's instructions. Samples were rehydrated and incubated for 1 hour in picrosirius red solution. After incubation, samples were briefly rinsed in 0.5% acetic acid, dehydrated in absolute ethanol, cleared, and mounted. Evaluation of picrosirius red staining was conducted using a Zeiss AxioScanner.Z1 (Carl Zeiss, Oberkochen, Germany). Full scans of 24-week-old Atg7 kidneys were acquired at a resolution of 200× using a Zeiss Axio Scan.z1 slide scanner equipped with a Hitachi HV-F202FCL digital video camera (Hitachi, Tokyo, Japan). Images were captured and processed using ZENblue software (Carl Zeiss SpA).

Electron microscopy

Primary cells. Cultured mPTCs were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) at 37°C for 1 hour, followed by post-fixation in 1% osmium tetroxide and 1.5%

potassium ferrocyanide in 0.1 M cacodylate on ice for 1 hour. After washing in distilled water, samples were stained with 0.5% uranyl acetate in water overnight at 4°C. Dehydration was performed in a graded ethanol series, followed by embedding in Epon 812 and curing at 60°C for 48 hours. Ultrathin sections (70–90nm) were cut using a Leica Ultracut UCT ultramicrotome, collected on copper grids, and stained with uranyl acetate and Sato's lead citrate. Imaging was conducted using a FEI Talos 120kV transmission electron microscope with a 4k×4K Ceta CMOS camera. Autophagic vacuoles (AVs) were identified and categorised as autophagosomes or autolysosomes, based on established criteria.[17] At least 20 randomly selected cellular profiles were analysed using ImageJ software to quantify AVs by calculating the percentage of cytosolic area occupied.

Zebrafish larvae. Animals were fixed in 2.5% glutaraldehyde and 1.6% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4) overnight after tail cutting. After rinsing in 0.1 M cacodylate buffer, larvae were post-fixed in 1% osmium tetroxide in cacodylate buffer for 40 minutes at room temperature and stained with 1% aqueous uranyl acetate for 1 hour at room temperature. Samples were dehydrated through a graded ethanol series, infiltrated with Epon812 at 60°C for 28 hours, and then sectioned into 350 nm semi-thin sections using a Leica EM FCS ultramicrotome. Sections were stained with Toluidine blue solution. Ultra-thin sections of 60 nm were collected onto formvar-coated copper grids, stained with lead phosphate dilution in water, and examined using an electron microscope (Philips CM100) at 80kV.

Sample preparation and immunoblotting. Proteins from animal tissues or cultured mPTCs were extracted using a lysis buffer containing protease inhibitors (Roche) and phosphatase inhibitors (PhosSTOP, Sigma). The lysates were sonicated and centrifuged at 10,000 × g for 10 min at 4°C. Protein concentrations were normalised (20 µg/lane), and samples were mixed with 4x Laemmli Sample Buffer (BioRad, 1610747) and separated by SDS-PAGE under reducing conditions. Proteins were then transferred onto PVDF membranes, which were blocked with 5% non-fat milk (Bio-Rad Laboratories, 1706404), followed by overnight

incubation at 4°C with primary antibodies. After washing, membranes were incubated with peroxidase-labelled secondary antibodies, and protein bands were visualised using enhanced chemiluminescence (Millipore, WBKLS0050) and imaged with a ChemiDoc MP imaging system (Bio-Rad Laboratories). Signal intensities were quantified by measuring the relative density of each band normalised to β-actin using ImageJ software.

Extracellular flux analysis and metabolic measurements. OCRs in mPTCs were assessed using XFp Extracellular Flux Analyzers from Agilent Seahorse Biosciences. Cells were cultured in XF-Base Medium (non-buffered RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, and 10 mM glucose, pH 7.4). OCR was measured under basal conditions and after the sequential addition of specific inhibitors using the XFp Cell Mito Stress Test Kit (Agilent Seahorse Biosciences). The inhibitors included 2μM Oligomycin (to inhibit ATP synthase), 0.5μM FCCP (to uncouple mitochondrial respiration), and 1μM Rotenone/Antimycin A (to inhibit complex I and III of the mitochondrial electron transport chain). All OCR measurements were normalised to cell numbers using the TC10TM automated cell counter from Bio-Rad. This method allows for the assessment of mitochondrial function and cellular respiration dynamics in mPTCs.

Cell proliferation. To assess the rate of proliferation, we used the Click-iT Plus EdU Alexa Fluor 488 Imaging Kit (C10637 Life Technologies). Cells were incubated with EdU solution for 16 h at 37 °C and processed following the manufacturer's instructions. DAPI (4′,6-diamino-2-phenylindole dihydrochloride) was used to counterstain nuclei. Analyses were performed by using the "Cytoplasm-Nucleus Translocation Assay" (CellProfiler[49]) to score the number of BrdU-positive nuclei.

Analysis of TCGA gene expression and survival data on cell renal cell carcinoma samples. The Genebass browser (https://app.genebass.org/) provided detailed coefficients and p-values from burden tests assessing the association between Chapter II neoplasms

(labelled with ICD10 codes) and pLOF alleles in *ATG7*. The entire cohort for clear cell renal cell carcinoma (KIRC) was downloaded from TCGA (The Tissue Cancer Genome Atlas). It included transcriptomic (in FPKM) and clinical data from 537 patients. In the first step of filtering, data from patients with insufficient clinical data for survival analysis were removed. Additionally, data from patients who had multiple RNA-seq performed on the same sample from tumour tissue were excluded. 525 patients remained after filtering, and 72 had available data from adjacent normal tissue samples to the primary tumour (Normal Tissue). The total number of samples obtained amounts to 597 RNA-seq samples from 525 patients. The entire data analysis was performed locally with Python (v. 3.11.5) using Pandas (v. 2.2.3), Numpy (v. 1.24.3), and glob libraries. The division into tertiles was performed using Numpy, considering only the gene expression of *ATG7* in the primary tumour data. The normal tissue samples were assigned to the tertile of the corresponding primary tumour. Survival analyses were performed considering only the 525 transcriptomic data from tumour tissues (Primary Tumour). These analyses were performed using the lifelines library (v. 0.30.0). Violin plots were generated using the Seaborn (v. 0.11.2) and Matplotlib (v. 3.7.2) libraries, considering the transcriptomic data from both the 72 normal tissue samples and the 525 primary tumour samples.

Data Collection and Integration Using PandaOmics AI Platform. The PandaOmics AI platform (Insilico Medicine, Hong Kong, China) is a cloud-based software tool that leverages artificial intelligence and bioinformatics to analyse multimodal omics and biomedical text data for the discovery of therapeutic targets and biomarkers.[50] This platform was utilised to integrate omics datasets from the Gene Expression Omnibus and ArrayExpress, combining these with samples of clear cell renal cancer tissues and adjacent normal kidney samples. Gene expression data were uploaded to PandaOmics, normalised and pre-processed following the standard protocols provided by the platform.

Differential expression and pathway enrichment analyses. The ccRCC gene signature was derived through a PandaOmics meta-analysis, which incorporated data from seven comparisons across seven distinct transcriptomic datasets. Differential expression analysis was conducted in PandaOmics utilising the limma R package, with each dataset processed following standard limma protocols. Gene-wise p-values were adjusted using the Benjamini-Hochberg correction method. PandaOmics calculated combined log-fold changes (LFC) across transcriptomics datasets using the 'Expression' feature. This feature calculates combined LFC values and Q-values across all datasets used for the analysis, employing min-max normalisation for LFC values and Stouffer's method for p-value aggregation, followed by additional FDR correction. All differentially expressed genes (DEGs) were subsequently downloaded and used to construct the final gene expression signature. Pathway enrichment analysis was performed with the GSEApy package prerank function according to standard protocols. For the prerank protocol, each gene was ranked according to the value derived from the multiplication of LogFoldChange and -log10(p-value) obtained from differential expression analysis results. MSigDB and Reactome databases were selected as the gene set from the GSEApy internal library for signalling pathway enrichment analysis.

Single-cell RNA sequencing analysis. Single-cell RNA sequencing (scRNA-seq) data from 167,283 cells from multiple tumour regions, lymph nodes, normal kidneys, and peripheral blood of two immune checkpoint blockade (ICB)-naïve and four ICB-treated ccRCC patients were collected from the Krishna et al.[40] Cell type annotations were derived from the original publication, as well as normalised counts, and dimensionality reduction post-batch correction for the UMAP. Differential expression between ccRCC and control samples for each cell type was calculated using the tl.rank_genes_groups function (method='Wilcoxon'). ATG7 expression levels (non-zero values) were plotted with corresponding p-values (threshold: 0.05) using the Plotly package.

Statistics and reproducibility. The data were presented as mean ± SEM. Statistical analyses were conducted using appropriate tests: one-way analysis of variance (ANOVA) with Tukey's, Sidak's, or Dunnett's post hoc tests for multiple comparisons between experimental groups, as required. For comparisons between two groups, two-tailed Student’s t-tests were used as appropriate. Normality was assessed using the D’Agostino and Pearson omnibus test. Non-parametric data were analysed using the Kruskal-Wallis test with Dunn's multiple comparison correction. Survival estimates were generated using the Kaplan–Meier method and compared using log-rank tests. Outliers were identified using the ROUT method (Q=1%). The sample size for each experimental group is detailed in the figure legends. Statistical significance levels are denoted by symbols, and the exact P-values are provided in the figure legends along with the specific statistical tests used. Each experiment was independently performed at least two to three times unless otherwise specified in the figure legends, and successful replication was achieved in all instances. Experimenters were not blinded to allocation during most experiments, except for experiments involving zebrafish larvae. GraphPad Prism software version 9.4.1 (GraphPad Software) was used for all statistical analyses and figure generation.

References

1. Palm, P. & Thompson, C.B. (2017). Nutrient acquisition strategies of mammalian cells. Nature 546, 234-242.

2. Keller, S. A. et al. (2023). Drug discovery and therapeutic perspectives for proximal tubulopathies. Kidney International 6, 1103-1112.

3. Nielsen, R., Christensen, E.I., Birn, H. (2016). Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney International 89, 58-67.

4. Cullen, P. J. & Steinberg, F. (2019). To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nature Reviews Molecular Cell Biology 19, 679-696.

5. Mizushima, N. & Levine, B. (2020). Autophagy in human diseases. New England Journal of Medicine 381, 1564-1576.

6. Festa, B. P. et al. (2018). Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney. Nature Communications 9, 161.

7. Berquez, M. et al. (2023). Lysosomal cystine export regulates mTORC1 signalling to guide kidney epithelial cell fate specialization. Nature Communications 14, 3994.

8. Yamamoto, H. et al. (2023). Autophagy genes in biology and disease. Nature Reviews Genetics 24, 382-400.

9. Nakatogawa, H. (2020). Mechanisms governing autophagosome biogenesis. Nature Reviews Molecular Cell Biology 21, 439-458.

10. Komatsu, M., Waguri, S., Ueno, T. et al. (2005). Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. Journal of Cell Biology 169, 425-434.

11. Klionsky, D. J. et al. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17, 1-382.

12. Collier, J. J. et al. (2021). Emerging roles of ATG7 in human health and disease. EMBO Molecular Medicine 13, e14824.

13. Komatsu, M. et al. (2006). Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880–884.

14. Kimura, T. et al. (2011). Autophagy protects the proximal tubule from degeneration and acute ischemic injury. Journal of American Society of Nephrology 22, 902–913.

15. Liu, S. et al. (2012). Autophagy plays a critical role in kidney tubule maintenance, aging, and ischemia-reperfusion injury. Autophagy 8, 826–837.

16. Wang, Z. M. et al. (2010). Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am. J. Clin. Nutr. 92: 1369–1377.

17. van der Rijt, S. et al. (2022). Immunometabolic rewiring of tubular epithelial cells in kidney disease. *Nature Reviews Nephrology* 18, 588-603.

18. Bhargava, P. and Schnellman, R.G. (2017). Mitochondrial energetics in the kidney. Nature Reviews Nephrology 13, 629-646.

19. Dijon, P. et al. (2021). The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation. Cell Metabolism 33, 379-384.

20. Doke, T., Mukerjee, S., Mukhi, D. et al. (2023). NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury. Nature Metabolism 5, 414-430.

21. Collier, J. J. Et al. (2021). Developmental consequences of defective ATG7-mediated autophagy in humans. New England Journal of Medicine 384, 2406-2417.

22. Iwano, M. et al. (2002). Evidence that fibroblasts derive from epithelium during tissue fibrosis. Journal of Clinical Investigation 110, 341-350.

23. Perez Bay, A. E. et al. (2016). The fast-recycling receptor Megalin defines the apical recycling pathway of epithelial cells. Nature Communications 7, 11550.

24. Jo, Y. S. et al. (2015). Phosphorylation of the nuclear receptor corepressor 1 by protein kinase B switches its corepressor targets in the liver of mice. Hepatology 62, 1606–1618.

25. Liu, G. Y. & Sabatini, D. M. (2020). mTOR at the nexus of nutrition, growth, ageing and disease. Nature Reviews Molecular Cell Biology 21, 183-203.

26. Singh, R. et al. (2009). Autophagy regulates lipid metabolism. Nature 458, 1131–1135.

27. Nguyen, T. B., et al. (2017). DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. Developmental Cell 42, 9-21.

28. Morant-Ferrando, B., et al. (2023). Fatty acid oxidation organizes mitochondrial supercomplexes to sustain astrocytic ROS and cognition. Nature Metabolism 5, 1290-1302.

29. Cunha, L. D. et al. (2018). LC3-associated phagocytosis in myeloid cells promotes tumor immune tolerance. Cell 175, 429–441.

30. Heckmann, B. L. et al. (2019). LC3-associated endocytosis facilitates beta-amyloid clearance and mitigates neurodegeneration in murine Alzheimer's disease. Cell 178, 536–551.

31. Kumar, A. V. et al. (2023). Lipid droplets modulate proteostasis, SQST-1/SQSTM1 dynamics, and lifespan in C. elegans. iScience 26, 107960.

32. MacRoe, C. A. & Peterson, R. T. (2015). Zebrafish as tools for drug discovery. Nature Reviews Drug Discovery 14, 721–730.

33. Chen, Z. et al. (2020). Transgenic zebrafish modelling low-molecular-weight proteinuria and lysosomal storage diseases. Kidney International 97, 1150-1163.

34. Verma et al. (2024). Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science 385, 275.

35. Levine, B. & Kroemer, G. (2019). Biological functions of autophagy genes. Cell 176, 11-42.

36. Pan, X. et al. (2023). Molecular subtyping and characterisation of clear cell renal cell carcinoma by tumour differentiation trajectories. iScience 26, 108370.

37. Tan, S. K. et al. (2023). Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. Nature Reviews Urology 20, 48-59.

38. Karczewski, K. J., et al. (2022). Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. Cell Genomics 2, 100168.

39. Tang, Z. et al. (2019). GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Research 47, W556-560.

40. Krishna, C. et al. (2021). Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumour topology and therapy efficacy. Cancer Cell 39, 662-677.e6.

41. Galluzzi, L. & Green, D. (2019). Autophagy-Independent Functions of the Autophagy Machinery. Cell 17, 1682-1699.

42. Mitrofanova, A., Merscher, S., and Fornoni, A. (2023). Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. *Nature Reviews Nephrology* 19: 629–645.

43. Miceli, C., et al. (2020). The primary cilium and lipophagy translate mechanical forces to direct metabolic adaptation of kidney epithelial cells. Nature Cell Biology 22, 1091-1102.

44. Geng, T.T., et al. (2024). Nuclear magnetic resonance-based metabolomics and risk of CKD. Am J Kidney Dis. 83, 9-17.

45. Ganley, I. (2021). The Importance of Being Autophagic. N. Engl. J. Med. 384**,** 2449-2450.

46. Olzmann, J.A., & Carvalho, P. (2019). Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 20, 137–155.

47. Liu, Y. et al. (2018). Hydroxysteroid dehydrogenase family proteins on lipid droplets in bacteria, C. elegans, and mammals. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1863, 881–894.

48. Alshehry, Z. H., Barlow, C. K., Weir, J. M.; Zhou, Y., McConville, M. J., Meikle, P. J. (2015). An efficient single-phase method for extracting plasma lipids. Metabolites 5, 389–403.

49. Carpenter, A. E., Jones, T. R., Lamprecht, M. R. et al. (2006). CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100.

50. Kamya, P. et al. (2024). PandaOmics: An AI-driven platform for therapeutic target and biomarker discovery. J. Chem. Inf. Model. 64, 3961–3969.

Acknowledgements

We thank Nadine Nägele and Marco Garbelli for technical help, the Center for Microscopy, and Image Analysis at the University of Zurich for providing equipment and confocal microscopy assistance, and the Functional Genomics Center at the University of Zurich for assistance. We thank C.W. Li, P. Nanni, and S. Streb (Functional Genomics Center Zurich, University of Zurich) for their advice and constructive suggestions. We acknowledge Euro-Bioimaging (www.eurobioimaging.eu) for providing access to imaging technologies and services via the Italian Node (ALEMBIC, Milan, Italy). We are grateful to the Cystinosis Research Foundation [Irvine, CA, USA; project grants CRFS-2017-007 (O.D. and A.L.), CRFS-2020-005 (O.D. and A.L.) and CRFS-2023-003 (O.D. and A.L.)], the Swiss National Science Foundation (project grant 310030_215715 to A.L.; and project grant 310030_204470 to C.M.), the University Research Priority Program of the University of Zurich (URPP) ITINERARE-Innovative Therapies in Rare Diseases (O.D. and A.L.). R.W.T. and R.M. are funded by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Medical Research Council (MR/W019027/1), the Lily Foundation, the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children. R.W.T. also receives additional funding from LifeArc and the Pathological Society. Postdoc Mobility-Stipendien of the Swiss National Science Foundation Grants P2ZHP3_195181 and P500PB_206851, Kidney Research UK Grant Paed_RP_001_20180925 support EO. Discovery Grant (NSERC), a Project Grant (CIHR) and a Research Chair in Precision Medicine (J. Louis Levesque Foundation – NB Research) support LRL.

Authors contributions

A.L. and O.D. conceived and supervised the study. D.N., S.K., O.D., and A.L. designed the experiments. D.N. and S.K. conducted immunoblotting analysis, RNA interference, gene expression experiments, confocal microscopy, live-cell imaging, molecular biology studies, and data analysis. L.P. conducted confocal microscopy studies of lipid droplet biology and lipophagy flux, analysed and interpreted the data. Z.C. generated the *atg7* knockout zebrafish model and, together with D.N., performed complementation experiments in zebrafish larvae and data analysis. A.R. carried out electron microscopy studies and data analysis. V.B. performed deconvolution of MAP1BLC3-positive autophagosome structures in the zebrafish pronephros and analysed the data. M.B. and P.K. conducted differentiation and proliferation studies and data analysis. M.Z., M.R., and A.O. performed metabolomics- and lipidomics-based studies and data analysis. R.M., R.W.T., A.M.S., E.G.O., and J.A.S. provided urine samples from two patients with loss-of-function *ATG7* variants and intellectual feedback. S.N. supervised D.N. in zebrafish swimming behaviour analysis. C.M. provided *Fip200* and *Atg5* floxed mouse lines and intellectual feedback. A.U. and M.K. analysed publicly available microarrays and bulk and single-cell RNA sequencing of ccRCC patient samples using artificial intelligence and data analysis. R.P., F.C., and E.R. performed genome-wide and phenome-wide association studies, gene expression, and survival analyses in ccRCC patients, along with statistical testing. A.M.O. carried out lipid droplet, autophagy, and bioenergetic studies in worms and performed data analysis. L.R.L. supervised A.M.O. and provided intellectual feedback. A.L. and O.D. drafted and edited the manuscript, incorporating input and comments from all authors. All authors approved the final version of the manuscript.

Declaration of interests

A.U. and M.K. are employed by Insilico Medicine, a commercial company focused on developing artificial intelligence-driven solutions for aging research, drug discovery, and longevity medicine. The other authors declare no competing interests.

Figure legends

Figure 1. *Atg7*$^{PT\text{-}KO}$ mice display growth defects, nutrient dyshomeostasis and proximal tubulopathy. (**A**) Schematic of the experimental workflow. (**B**) Body weight measurements of *Atg7* mice at 4, 12, and 24 weeks, n=20 mice per genotype. (**C**) Representative images of *Atg7* mice at 24 weeks of age. (**D**) Urinary excretion levels of the low-molecular-weight CC16 protein at the indicated times. At 4 weeks of age: n=19 CTR and n=20 *Atg7*$^{PT\text{-}KO}$ mice; at 12 and 24 weeks of age: n=20 mice per genotype. (**E**) Quantification of urinary albumin from 24-week-old *Atg7* mice; n = 8 mice per genotype. (**F**) Representative immunoblots and quantification of the indicated proteins in the urine samples from 24-week-old *Atg7* mice, n=6 animals per genotype. (**G**-**H**) Quantification of (**G**) glucose and (**H**) phosphorus in the urine of 24-week-old *Atg7* mice. For (**G**), n=15 CTR and 17 *Atg7*$^{PT\text{-}KO}$ mice; for (**H**), n=19 mice per genotype. (**I**) Quantification of urinary amino acid levels in 24-week-old *Atg7* mice, n=5 animals per genotype. Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartate; Cys, cysteine; Gln, glutamine; Glu, glutamate; Gly, glycine; His, histidine; Hyp, hydroxyproline; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Orn, ornithine; Phe, phenylalanine; Pro, proline; Ser, serine; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine. All urinary parameters were normalised to creatinine concentration. Bar graphs show mean ± SEM. Statistics were calculated using unpaired two-tailed Student's *t*-test, *P < 0.05, **P < 0.01, ***P < 0.001, and $^{\#}$P < 0.0001 relative to CTR. NS, not significant.

Figure 2. ATG7 loss diverts the functional states of the PT cells towards growth and proliferation. (**A**) Schematic of the experimental workflow used for assessing endocytosis in the kidneys of *Atg7* mice. (**B**) Confocal imaging and quantification of Cy5-(red) or Alexa 647-Dextran (green) fluorescence intensities in the Aqp1^{+} PT segments (grey) of *Atg7* murine kidneys; n=60 PT segments pooled from 2 mice per genotype. (**C**) mRNA expression of the indicated genes in the kidney cortex of 24-week-old *Atg7* mice, n=7 animals per genotype. (**D**) Confocal imaging and quantification of Lrp2 (red) fluorescence intensity in the LTL^{+}

(green) PT of *Atg7* murine kidneys; n=100 PT segments pooled from 2 mice per genotype. (**E**) mRNA expression of the indicated genes in the kidney cortex of 24-week-old *Atg7* mice, n=7 animals per genotype. (**F**) Confocal microscopy and quantification of the percentage of $PCNA^+$ (red) nuclei in the LTL^+ (green) PT segments of *Atg7* mouse kidneys; n=90 PT segments pooled from 2 animals per genotype. Nuclei counterstained with DAPI (blue or grey). Bar graphs show mean ± SEM. Statistics were calculated using unpaired two-tailed Student's *t*-test, *P < 0.05, ***P < 0.001, and #P < 0.0001 relative to CTR. NS, not significant. Scale bars, 25µm.

Figure 3. ATG7 deficiency impairs autophagy, triggering loss of differentiation and proliferation in cultured PT cells. (**A**) Schematic of the workflow for culturing primary cells derived from PT segments of *Atg7* mouse kidneys. (**B,D**) Immunoblots (**B**) and quantification (**D**) of the indicated proteins in mPTCs from 24-week-old *Atg7* mouse kidneys, n=3 biologically independent experiments. (**C,E-G**) mPTCs from *Atg7* mouse kidneys were cultivated under fed or starved conditions, or starved conditions in the presence of BafA1 (250 nM for 4 h). (**C, E**) Immunoblots (**C**) and quantification (**E**) of the indicated proteins, n=6 biologically independent experiments. (**F**) Confocal imaging and quantification of the number of $Map1lc3^+$ structures. Fed conditions: n=1570 CTR and 1413 $Atg7^{PT\text{-}KO}$ cells. Starved conditions: n=910 CTR and 1548 $Atg7^{PT\text{-}KO}$ cells, pooled from 3 biologically independent experiments. (**G**) Representative electron micrographs and quantification of cytoplasm area occupied by autophagy vacuoles or lysosome/multivesicular bodies (expressed as the percentage of the total area). AVs distribution: n=48 CTR and 40 $Atg7^{PT\text{-}KO}$ cells pooled from 2 biologically independent experiments. Lysosomes/MVBs distribution: n=48 CTR and 38 $Atg7^{PT\text{-}KO}$ cells pooled from 2 biologically independent experiments. Green and purple indicate EM-compatible AVs or Lys/MVBs, respectively. (**H**) mRNA expression of the indicated genes in mPTCs from 24-week-old *Atg7* mice, n=8 biologically independent experiments. (**I**) Confocal imaging and quantification of EdU^+ cells (expressed as a percentage of total cells); n=84 CTR and 95 $Atg7^{PT\text{-}KO}$ cells from 3 biologically independent

experiments. (**J**) Confocal microscopy and quantification of BSA+ structures per cell; n=2096 CTR and 1833 *Atg7*$^{PT-KO}$ cells from 3 biologically independent experiments. Nuclei counterstained with DAPI (blue or grey). Bar graphs show mean ± SEM. Statistics were calculated by unpaired two-tailed Student's t-test *P < 0.05, **P < 0.01, ***P < 0.001, $^{\#}$P < 0.0001 relative to fed CTR or starved CTR or starved *Atg7*$^{PT-KO}$. NS not significant. Scale bars, 25µm in (**F**), (**I**) and (**J**).

Figure 4. ATG7 loss impairs autophagic degradation of LDs, compromising FA metabolism and energy production. (**A**) KEGG pathway enrichment analysis. The black dashed line marks the threshold for significance. Black circles indicate the enriched proteins and metabolites in *Atg7* mPTCs compared to CTR, n=4 biologically independent experiments. *P* values were calculated using Omicsnet2.0. (**B**) Confocal imaging and quantifications of the number of LDs (LipidTOX, magenta) and LipidTOX/Sqstm1 (green) colocalization (%). Number: n=158 fed, 242 starved, and 200 BafA1-treated, starved CTR cells; and n= 212 fed, 228 starved, and 208 BafA1-treated, starved *Atg7*$^{PT-KO}$ cells. Colocalization (%): n=42 fed, 43 starved, 50 BafA1-treated, starved CTR cells; and n=51 fed, starved, BafA1-treated, starved *Atg7*$^{PT-KO}$ cells. (**C**) Heat map of lipid changes in *Atg7* mPTCs. (**D**) Schematic of the experimental workflow for tracking FA flux into the mitochondria using Green-C16. (**E**) Confocal imaging and quantification of Bodipy-C16-TOMM20^{+} colocalization score (n=15 fields from 3 biologically independent experiments). Insets show high-magnification views. (**F**) Oxygen consumption rates (OCRs) of basal respiration, mitochondrial ATP production and maximal respiration; n = 9 replicates from 3 biologically independent experiments. (**G, H**) Quantification of TMRM and MitoSOX fluorescence intensity; n = 20 cells from 2 biologically independent experiments. Representative images shown in **Figures S10D** and **S10E**. Bar graphs show mean ± SEM. Statistics were calculated by one-way ANOVA followed by Tukey's multiple comparisons test in (**B**) and by unpaired two-tailed Student's t-test in **(E, F, G, H)** *P < 0.05,

**P < 0.01, ***P < 0.001, #P < 0.0001 relative to fed/starved CTR or fed/starved *Atg7*$^{PT\text{-}KO}$ cells. NS, not significant Nuclei counterstained with DAPI (blue or grey). Scale bars, 10µm.

Figure 5. Cell-autonomous role of ATG7 in PT metabolism and differentiation. (**A,B**) Quantification of the indicated proteins, n=3 (in **A**) and 5 (in **B**) biologically independent experiments. (**C**) Confocal imaging and quantification of the number of LDs (LipidTOX, magenta). Empty: n=167 fed, 223 starved , 220 BafA1-treated, starved cells; + Cre: n=287 fed, 210 starved, and 242 BafA1-treated, starved cells. (**D**) Schematic of the experimental workflow for monitoring the autophagic degradation of LDs. (**E**) Confocal imaging and quantification of LD number (LipidTOX, magenta), Plin2 (magenta)-Sqstm1 (green), and LipidTOX/Lamp1 (green) colocalization (%). Plin2/Sqstm1 colocalization: Empty: n=39 fed, 48 starved, 43 BafA1-treated, starved cells; + Cre: n=45 fed or starved, 48 BafA1-treated, starved cells. Number: Empty: n=180 fed, 169 starved, and 198 BafA1-treated, starved cells; + Cre: 225 fed and 210 starved, and 242 BafA1-treated, starved cells. LipidTOX/Lamp1 colocalization: Empty: n=56 fed, 60 starved, and 61 BafA1-treated, starved cells; + Cre: n= 64 fed, 52 starved, and 53 BafA1-treated cells. (**F**) Oxygen consumption rates (OCRs) of basal respiration, mitochondrial ATP production and maximal respiration; n=8 replicates from 2 biologically independent experiments. (**G**) Confocal imaging and quantification of EdU^{+} cells; n=133 (Empty) and 130 (+ Cre) cells from 3 biologically independent experiments. (**H**) mRNA expression of the indicated genes, n=7 biologically independent experiments. (**I**) Confocal imaging and quantification of BSA^{+} structures per cell; n = 466 (Empty) and 387 cells (+ Cre) from 4 biologically independent experiments. Nuclei counterstained with DAPI (blue). Plots show mean ± SEM. Statistics were calculated by one-way ANOVA followed by Tukey's multiple comparisons test in (**B**, **C**, **E**) and unpaired two-tailed Student's *t*-test in (**A**, **F-I**), *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.0001 relative to fed/starved cells transduced with Empty or with Cre. NS, not significant. Scale bars, 10µm.

Figure 6. Autophagy regulator atg7 has a conserved role in *C. elegans*. (**A**) Schematic of the experimental workflow for measuring autophagy, LDs, and whole-organism respiration in nematodes. (**B**) Light microscopy and quantification of RFP fluorescence intensity in wild-type and *atg7 (bp411)* mutant nematodes, n=10 animals per group. (**C**) Light microscopy and quantification of GFP fluorescence intensity in the intestine of both WT and *atg7 (bp411)* mutant nematodes, n=6 animals per group. (**D**) Oxygen consumption analysis in wild-type and *atg7(bp411)* nematodes at day 4 of adulthood, normalised to the number of nematodes, n=4 biologically independent experiments. Bar graphs show mean ± SEM. Statistics were calculated by unpaired two-tailed Student's t-test *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.0001 relative to wild-type nematodes.

Figure 7. Loss of atg7-dependent autophagy impairs homeostasis and the reabsorptive activities of zebrafish pronephros. (**A**) Kaplan-Meier survival curves, n = 21 *atg7*^{WT} and 17 *atg7*^{KO} zebrafish larvae. (**B**) Swimming tracking and (**C**) distance quantification in zebrafish larvae at 5,10,14, and 19 dpf; n = 29 *atg7*^{WT} and 27 *atg7*^{KO} zebrafish larvae at 5dpf, n = 32 *atg7*^{WT} and 20 *atg*7^{KO} zebrafish larvae at 10dpf, n = 64 *atg7*^{WT} and 21 *atg7*^{KO} zebrafish larvae at 14dpf, n = 52 *atg7*^{WT} and 24 *atg*7^{KO} zebrafish larvae at 19dpf. (**D**) Schematic of the experimental workflow used to measure autophagy in zebrafish larvae. (**E**) Multiphoton imaging and quantification of the number of MAP1LC3B^{+} structures, n = 7 zebrafish larvae per genotype. (**F**) Schematic of the experimental workflow used to assess PT function/tubular proteinuria in zebrafish larvae: ½vdbp-mCherry (~50 kDa) is produced in the liver, filtered by the glomerulus, reabsorbed by PT cells, and processed via the endolysosomal pathway (EE = early endosome, LE = late endosome, Lys = lysosome). (**G, H, J**) Quantification of urinary mCherry levels by ELISA; in (**G**), n = 19 *atg7*^{WT} and 20 *atg7*^{KO} zebrafish larvae at 10 dpf; and n=19 zebrafish larvae at 14 dpf; in (**H**), n = 20 *atg7*^{WT}, 19 *atg*7^{WT} + *hATG7*, 19 *atg*7^{KO}, and 16 *atg7*^{KO} + h*ATG7* zebrafish larvae; in (**J**) n=16 zebrafish larvae per condition. (**I**) Swimming tracking and (**C**) distance quantification in treated zebrafish; n= 46 in vehicle- and Etomoxir-treated zebrafish larvae.

Bar graphs show mean ± SEM. Statistics were calculated using unpaired two-tailed Student's *t*-test, **P < 0.01, ***P < 0.001 and #P < 0.0001 relative to *atg7*^{WT} or *atg7*^{KO}. NS, not significant. Scale bar, 200µm.

Figure 8. Association of *ATG7* variants with renal function-related traits and kidney disease risk. (**A**) Phenome-wide (PheWAS) for variant rs375156407, displaying phenome-significant association across traits from the MVP biobank related to nephritis and nephropathy. Traits are sorted and coloured according to a meaningful set of biological categories. The grey line shows the phenome-wide significance threshold. The direction of effect of the alternative allele's association with each trait is exhibited by upward-facing (positive effect) or downward-facing (negative effect) triangles. (**B**) HuGe score indicates an association between the *ATG7* gene and traits catalogued from the Common Metabolic Diseases Knowledge Portal. The yellow lines show the significance threshold.

Figure 9. ATG7 modulates differentiation and metabolism, affecting the prognosis of patients with ccRCC. (**A, right**) *ATG7* expression in healthy vs. tumour tissues across low vs medium/high *ATG7* expression tertiles. *ATG7* FPKM values in normal solid and primary tumour tissues, respectively. Comparisons between individuals in the low-expression tertile (left) and those in the medium/high-expression tertiles (right). *P*-values were calculated using the Wilcoxon test. (**A, left**) Kaplan-Meier survival curves of individuals with KIRC stratified by *ATG7* expression in tumour tissue. Individuals in the low-expression tertile (blue curve) were compared to those in the medium/high-expression tertiles (red curve). Significance was assessed using the log-rank test. (**B**) Schematic of the transcriptomic analysis pipeline. Publicly available datasets of ccRCC were integrated using PandaOmics. Meta-analysis was performed to assess gene expression and conduct pathway enrichment using MSigDB and Reactome databases. (**C**) Heat maps showing mRNA expression of *ATG7*, PT-specific markers, and proliferation/dedifferentiation genes in ccRCC tumour tissues vs. adjacent normal tissues. Differential expression and combined log fold change (LFC) analyses were conducted using PandaOmics' 'Expression' feature. (**D**) Heat map and UMAPs displaying

ATG7 mRNA expression across different cell populations in untreated ccRCC tumour tissues compared to adjacent normal kidney samples. Statistical significance was assessed using the Wilcoxon test ($P < 0.05$).

Figure 10. Autophagy regulator ATG7 as a conserved metabolic switch that underpins epithelial cell fate, kidney health, and disease. Specialized epithelial cells must integrate metabolic programs with differentiation cues to execute their unique functions and preserve homeostasis. In the kidney proximal tubule, ATG7-dependent autophagy emerges as a linchpin in this integration, steering cells along metabolic and differentiation trajectories that support their reabsorptive and homeostatic demands. Loss of ATG7 shifts cells into an anabolic, proliferative state, eroding their differentiated identity and functional specialization. At the mechanistic level, ATG7 deficiency blocks lipophagy, trapping lipid droplets and starving mitochondria of fatty acids — this defect impairs oxidative metabolism in both nematode and mouse cells and collapses cellular energy balance. Across vertebrate models (zebrafish to mouse), these metabolic failures translate into defective solute transport, urinary wasting of essential nutrients, and proximal tubulopathy. Clinically, common and rare *ATG7* variants associate with cardio–renal–metabolic traits and elevated kidney disease risk, and reduced ATG7 expression predicts poorer survival in clear cell renal carcinoma.

Figure 1


A
CTR
Atg7PT-KO
Urine samples
Age (weeks)
4
12
24
Readouts:
• Body weight and growth
• Tubular proteinuria
• Glucosuria
• Phosphaturia
• Aminoaciduria
B
CTR
Atg7PT-KO
Body weight g
ns
***
***
Age (weeks): 4 12 24
C
24-week-old mice
CTR
Atg7PT-KO
D
CTR
Atg7PT-KO
CC16 mg/g creatinine
#
#
#
Age (weeks): 4 12 24
E
MW (KDa)
CTR
Atg7PT-KO
BSA (40µg)
200
150
100
75
50
37
CTR
Atg7PT-KO
Albumin in the urine relative to CTR
#
G
CTR
Atg7PT-KO
Glucose mg/g creatinine
*
F
CTR
Atg7PT-KO
MW (KDa)
TF
Vdbp
75
50
CTR
Atg7PT-KO
Protein target relative to CTR
**
***
TF
Vdbp
H
CTR
Atg7PT-KO
Phosphorus mg/g creatinine
*
I
CTR
Atg7PT-KO
High
Low
Neutral
Ser
Thr
Asn
Gln
Tyr
Trp
Ala
Gly
Ile
Leu
Val
Met
Cys
Phe
Pro
Basic
Arg
His
Lys
Acid
Asp
Glut
CTR
Atg7PT-KO
Amino acids mmol/mol creatinine
**
ns
ns
*
*
*
**
Ser
Thr
Asn
Val
Met
Cys
Arg

Figure 2


A
•Alexa647-Dextran
•Cy5-β-lactoglobulin
γ Receptors
Endocytosis:
1) Receptor-mediated
2) Fluid-phase
B
CTR
Atg7PT-KO
G
Aqp1 Cy5-β-lactoglobulin Alexa647-Dextran DAPI
β-lactoglobulin fluorescence intensity per PT area
Dextran fluorescence intensity per PT area
C
Target gene/HRPT
Atg7
Lrp2
Cubn
Slc34a1
Slc5a2
PT-cell specific genes
D
Lrp2 fluorescence intensity per PT area
Lrp2 LTL DAPI
E
Ccna2
Pcna
Ki67
Cdc20
Ccnb2
Proliferation markers
NS
F
Pcna+ nuclei per PT area
Pcna LTL DAPI

Figure 3


A
CTR or Atg7PT-KO
Kidneys
Cortex samples
PT segments
mPTCs
B
CTR
Atg7PT-KO
MW (KDa)
Atg7
β–actin
75
37
C
Fed
Starved
BafA1
Map1Lc3b-I
Map1Lc3b-II
β-actin
20
37
D
Atg7/β-actin
E
Map1lc3b-II/β-actin
NS
F
Fed
Starved
Map1lc3b DAPI
Map1lc3b+ structures per cell
G
Starved + BfnA1
Distribution of autophagic vacuoles
Distribution of lysosomes/MVBs
ns
Autophagic vacuoles
Lysosomes/MVBs
H
Target gene/HRPT
Lrp2
Cubn
Ccna
Cdc20
Ccnb2
PT-cell specific genes
Proliferation markers
I
EdU DAPI
% of EdU+ nuclei
J
BSA DAPI
BSA+ structures per cell

Figure 4


A
Enriched KEGG terms (Atg7PT-cKO vs CTR mPTCs)
Fatty acid elongation
Fatty acid degradation
Branched amino acid degradation
Metabolism in cancer
Autophagy
Proteoglycans in cancer
Arginine biosynthesis
Alanine, aspartate, & glutamate met.
Cellular senescence
Renal cell carcinoma
Pathways in cancer
Cysteine and methionine
TCA cycle
Lysosome
Hits
5
15
41
-Log10 (integrated p value)
B
Fed
Starved
Starved + BafA1
CTR
Atg7 PT-KO
DAPI LipidTOX Sqstm1
LDs per cell
LipidTOX-Sqstm1 % colocalization
CTR
Atg7PT-KO
NS
Fed
Starved
BafA1
C
Log2(FC, KO vs. CTR)
Acyl Carnitines
Cardiolipins
Ceramides
Cholesterol Esters
Dihydroceramides
Ether-Phosphatidylcholines
Ether-Phosphatidylethanolamines
Hexosyl-ceramides
Hexosyl-dihydroceramides
Lysophosphatidylcholines
Lysophosphatidylethanolamines
Phosphatidylcholines
Phosphatidylethanolamines
Phosphatidylserines
Sphingomyleins
Trigylcerides
D
Pulse 24h in GM
Green-C16
Atg7 mPTCs
Chase 24h in GM
Mitochondria staining
Confocal microscopy
Green-C16/mitochondria colocalization
Lipid droplet
Mitochondrion
E
CTR
Atg7 PT-KO
Green-C16 Tomm20 DAPI
F
Colocalization score
OCRs pmol/min/10^4 cells
Basal respiration
ATP production
Maximal respiration
G
TMRM fluorescence intensity
H
MitoSOX fluorescence intensity

Figure 5


A
Atg7fl/fl
Empty
+ Cre
Empty
+ Cre
MW (KDa)
Atg7
β-actin
75
37
Atg7fl/fl mPTCs
Atg7/β-actin
***
B
Empty
+ Cre
Fed
Starved
BafA1
MW (KDa)
Map1Lc3b-I
Map1Lc3b-II
β-actin
20
37
Atg7fl/fl mPTCs
Map1lc3b-II/Map1lc3b-I
NS
C
Atg7fl/fl mPTCs
Empty
+ Cre
Fed
Starved
Starved + BafA1
Lipid droplets per cell
NS
DAPI LipidTOX
D
Pulse
Chase (16h)
+OA
Withdrawal
Starved media
± BafA1
mPTCs
• Fixation
• LipidTOX
• Lysosome or autophagy labelling
E
Fed
Starved
Starved + BafA1
+ OA; Atg7fl/fl
Empty
+ Cre
DAPI Plin2 Sqstm1
Plin2/Sqstm1 % colocalization
Lipid droplets per cell
DAPI LipidTOX Lamp1
LipidTOX-Lamp1 % colocalization
F
OCRs pmol/min/10⁴ cells
Basal respiration
ATP production
Maximal respiration
G
Atg7fl/fl mPTCs
Empty
+Cre
% of EdU+ nuclei
EdU DAPI
H
Target gene/HPRT
Lrp2
Cubn
PT-cell specific genes
I
Atg7fl/fl
Empty
+Cre
BSA+ spots per cell
BSA DAPI

Figure 6


A
Wild-type or atg7(bp411);
SQST-1::RFP
Wild-type or atg7(bp411);
DHS-3::GFP
Fluorescence microscopy:
• Autophagy (SQST1)
• Lipid droplets (DHS-3)
Wild-type or atg7(bp411)
Whole organism respiration
B
DIC
Wild-type
atg7 (bp411)
SQST-1::RFP
Wild-type
atg7 (bp411)
Mean fluorescence intensity (a.u.)
#
C
Proximal intestine
Midgut
Distal intestine
Wild-type
Atg7 (bp411)
DHS-3::GFP
Wild-type
atg7 (bp411)
Mean fluorescence intensity (a.u.)
#
Proximal intestine
Midgut
Distal intestine
D
Wild-type
atg7 (bp411)
pmol/s*mL
**

Figure 7


A
Survival rate (%)
Time (days)
atg7WT (n=21)
atg7KO (n=17)
p < 0.0001
#
B
Horizontal position (pxl)
KO/KO
WT/WT
WT/KO
KO/KO
KO/KO
KO/KO
WT/KO
WT/KO
WT/WT
WT/WT
C
atg7WT
atg7KO
Swimming distance mm
Age (dpf)
NS
NS
**
#
D
PiT1
mCherry
MAP1LC3b
atg7 WT
atg7 KO
Multiphoton microscopy
E
atg7WT
atg7KO
Pronephros
MAP1LC3b
MAP1LC3b+ structures per pronephros
**
F
atg7 WT or atg7 KO
(lfabp:1/2 vdbp-mCherry)
mCherry levels by ELISA
Receptors
G
mCherry levels pg/ml
Age (dpf)
NS
#
H
mCherry levels pg/ml
hATG7:
14 dpf
NS
#
#
I
Vehicle
Etomoxir
Swimming distance mm
***
J
Vehicle
Etomoxir
mCherry levels pg/ml
***

Figure 8


A
3:11483399_G/A (rs375156407)
Nearest gene: ATG7
AF ranges from 5.0e-4 to 9.0e-4
-Log10 (p-value)
Nephritis and nephropathy
Nephritis and nephropathy without mention of glomerulonephritis
Nephritis; nephrosis; renal sclerosis
Labs
Vitalis
Disease diagnosis
Survey family story
Survey vitalis
Infectious disease
Injuries
Other
Neoplasms
Endocrine/Metabolic
Hematopoietic
Neurological
Sensory organs
Circulatory system
Respiratory system
Digestive system
Genitourinary system
Dermatological
Musculoskeletal
Congenital anomalies
Symptoms
Survey smoking
B
Log (HuGE score)
Waist-hip ratio
Waist-hip ratio adj BMI
Hypertension
Systolic blood pressure
Pulse pressure
Diastolic blood pressure
Triglycerides
Blood urea nitrogen
eGFR creatinine
Cystatin C
Height
Weight
Body mass index (BMI)
HDL cholesterol
Anthropometric
Atrial fibrillation
Cardiovascular
Cerebrovascular
MRI traits
Diabetic complications
ECG traits
Glycemic
Hematological
Hepatic
Immunological
Lipids
Metabolite
Metformin response
Nutritional
Ocular
Other
Renal
Reproductive traits
Sleep and circadian
Stroke
Sulfonylurea response
Type 1 Diabetes

Figure 9


A
p=3.060e-78
p=1.603e-07
p=1.061e-09
n=175
n=12
n=384
n=50
ATG7 expression [FPKM]
Primary tumor
Normal tissue
Low-expression tertile
Medium/high expression tertiles
Medium/high expression in primary tumors (n=362;†=105)
Low-expression in primary tumors (n=173;†=68)
Survival probability
Days
p = 2.23e-02
B
TCGA-KIRK
GSE168845
E-TABM-282
GSE126964
GSE781
GSE76207
GSE26574
RNA-seq
Microarray
panda Omics
Combined Meta-analysis
656 ccRCC patients
146 normal controls
Expression analysis
MSigDB Hallmarks
Reactome pathways
C
Combined LogFC
TCGA-KIRC
GSE26574
GSE126964
GSE76207
GSE781
E-TABM-282
GSE168845
PT-cell-specific genes
SLC34A1
SLC5A2
CUBN
LRP2
SOX9
Proliferation Dedifferentiation
PCNA
CDC20
CCNA2
CCNB2
MIK67
VIM
Log2FC
D
ATG7 log fold change (tumor vs adjacent normal kidney)
Untreated 1
Untreated 2
Ambiguous
B cell
CD14+ Monocyte
CD14+/CD16+ Monocyte
CD4+ Activated IEG
CD4+ Effector
CD4+ Naive
CD4+ Proliferating
CD45- Myofibroblast
CD45- PAX8+ renal epithelium
CD45- Vascular Endothelium
CD45- ccRCC CA9+
CD8A+ Exhausted
CD8A+ Exhausted IEG
CD8A+ NK-like
CD8A+ Proliferating
CD8A+ Tissue-resident
Conventional NK
NK HSP+
TAM HLAhi
TAM HLAint
TAM ISGhi
TAM ISGint
TAM/TCR (Ambiguos)
cDC1
cDC2
pDC
ATG7 expression in tumor
ATG7 expression in adjacent normal kidney
UMAP1
UMAP2

Figure 10


Metabolism and differentiation maintain kidney tubule function and homeostasis
ATG7
Key Regulator of Kidney Tubule Epithelial Cell-Fate Specialization
Loss of ATG7
Autophagosomes
Lipid autophagy
Lipid droplets
Fatty acid metabolism
Cellular bioenergetics
Differentiation
Proliferation
Ligands
• Proximal tubule dysfunction
• Appearance in the urine of nutrients
• Kidney tubulopathy & disease onset
atg7 deficiency in zebrafish
• Altered behaviour
• Pronephros dysfunction
• Tubular proteinuria
• Shortened lifespan
atg7 deficiency in nematode
• Oxidative metabolism impairment
• Energy imbalance
PT-specific loss of ATG7 in mouse
• Growth defects
• Generalized PT dysfunction
• Tubular proteinuria
• Kidney tubulopathy
Genetic variation in ATG7 and low expression
• Cardiometabolic health
• Kidney function biomarkers
• Increased kidney disease risk
• Prognosis in renal cell carcinoma